[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4914
46. Ohson K, DesGroseilliers JP, Weatherhead S, Weatherhead L: Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy. J Cutan Med Surg; 2006 Jul-Aug;10(4):201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234120.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
  •  go-up   go-down


47. Hexsel CL, Eide MJ, Johnson CC, Krajenta R, Jacobsen G, Hamzavi I, Lim HW: Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo. J Am Acad Dermatol; 2009 Jun;60(6):929-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo.
  • BACKGROUND: Nonmelanoma skin cancer (NMSC) incidence in patients with vitiligo has not been studied.
  • Age-adjusted incidence rates were: basal cell carcinoma, male 1382/100,000; basal cell carcinoma, female 0; squamous cell carcinoma, male 465/100,000; squamous cell carcinoma, female 156/100,000.
  • Except for basal cell carcinoma in females, all rates were higher than US rates but not statistically significant.
  • [MeSH-major] Skin Neoplasms / epidemiology. Vitiligo / complications
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Female. Humans. Male. Middle Aged. United States / epidemiology

  • Genetic Alliance. consumer health - Vitiligo.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Vitiligo.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Am Acad Dermatol. 2009 Dec;61(6):1080-1 [19925933.001]
  • [Cites] Int J Cancer. 1991 Jan 2;47(1):12-9 [1985867.001]
  • [Cites] N Engl J Med. 1974 Dec 5;291(23):1207-11 [4422691.001]
  • [Cites] Clin Exp Dermatol. 1996 Jan;21(1):43-5 [8689768.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2003 Sep;17(5):578-80 [12941100.001]
  • [Cites] J Am Acad Dermatol. 1998 May;38(5 Pt 1):647-66; quiz 667-8 [9591808.001]
  • [Cites] N Engl J Med. 1979 Apr 12;300(15):809-13 [423919.001]
  • [Cites] J Am Acad Dermatol. 2005 Aug;53(2):320-8 [16021129.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):824-5 [10792246.001]
  • [Cites] Dermatol Surg. 2006 Dec;32(12):1473-9 [17199655.001]
  • [Cites] Clin Exp Dermatol. 1997 Jan;22(1):54 [9330057.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Arch Dermatol. 1995 Jun;131(6):734-5 [7778934.001]
  • [Cites] Int J Cancer. 1993 Apr 1;53(6):886-91 [8473047.001]
  • [Cites] Arch Dermatol. 1976 Nov;112(11):1531-4 [984858.001]
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):268-70 [9486686.001]
  • [Cites] Acta Derm Venereol. 1996 Nov;76(6):429-32 [8982403.001]
  • [Cites] J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8 [8176018.001]
  • [Cites] Acta Derm Venereol. 1992 Aug;72(4):305-6 [1357897.001]
  • [Cites] J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4 [17052479.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):667-73 [7804993.001]
  • [Cites] J Am Acad Dermatol. 2001 Dec;45(6 Suppl):S227-9 [11712068.001]
  • [Cites] Br J Dermatol. 2000 Jul;143(1):219-21 [10886181.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Aug;22(4):211-3 [16869872.001]
  • (PMID = 19375190.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA140754
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Yuan L, Goldbach A, Xu H: Segregation and H2 transport rate control in body-centered cubic PdCu membranes. J Phys Chem B; 2007 Sep 20;111(37):10952-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The membrane underwent a bcc-fcc (body-centered cubic to face-centered cubic) phase transition between 723 and 873 K resulting in compositional segregation.
  • After reannealing at 723 K the alloy layer reverted to a bcc structure although a small fcc fraction remained behind.
  • The mixed-phase morphology was analyzed combining X-ray diffraction with scanning electron microscopy-energy-dispersive spectroscopic analysis (SEM-EDS) measurements, which revealed micrometer-scale Cu-enriched bcc and Cu-depleted fcc domains.
  • The prevalence of desorption as the permeation rate-limiting step below 454 K is attributed to the pairing of an extraordinarily high hydrogen diffusivity with a marginal hydrogen solubility in bcc PdCu alloys.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715958.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Leite JL, Stolf HO, Reis NA, Ward LS: Human herpesvirus type 6 and type 1 infection increases susceptibility to nonmelanoma skin tumors. Cancer Lett; 2005 Jun 28;224(2):213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human herpesvirus type 6 and type 1 infection increases susceptibility to nonmelanoma skin tumors.
  • In order to investigate herpesvirus (HHV) role in the susceptibility to skin cancer, we compared HHV6 and HHV1 incidence in DNA samples extracted from 120 lesions and 41 normal skin tissues.
  • HHV6 (31.7%) and HHV1 (23.8%) were detected more frequently in skin cancer than in control individuals (14.6 and 5%, respectively) (P=0.0391 and P=0.00094, respectively).
  • The risk of presenting basal cell carcinomas (BCC) was more than 3 times higher for HHV-6 infected patients (OR=3.182; 95% CI: 1.125-8.997).
  • The risk for HHV-1 infected individuals of presenting BCC and squamous cell carcinomas was increased 8 and 6 times, respectively (OR=8.125; 95% CI: 1.735-38.043 and OR=6.290; 95% CI: 1.283-30.856, respectively).
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Herpes Simplex / complications. Herpesvirus 1, Human / pathogenicity. Herpesvirus 6, Human / pathogenicity. Roseolovirus Infections / complications. Skin Neoplasms / etiology. Skin Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Case-Control Studies. Child. DNA, Viral / analysis. Female. Humans. Incidence. Male. Middle Aged. Odds Ratio. Polymerase Chain Reaction. Risk Factors

  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15914272.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


50. Goldberg M, Rummelt C, Laerm A, Helmbold P, Holbach LM, Ballhausen WG: Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas. Br J Dermatol; 2006 Dec;155(6):1154-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
  • BACKGROUND: Extensive exposure to ultraviolet radiation is associated with genetic alterations in basal cell carcinomas (BCCs), which represent some 75% of skin cancers.
  • OBJECTIVES: As recent data suggested the fragile histidine triad (FHIT) gene product to participate in DNA damage responses we wished to address whether functional deletion of this tumour suppressor participates in the development of BCC.
  • METHODS: Paraffin-embedded specimens from 17 patients with BCC were available for methylation-specific polymerase chain reaction (MSP), combined bisulphite-dependent restriction analysis (COBRA) of the FHIT gene and immunohistochemistry of its product.
  • RESULTS: We report for the first time that 100% of BCCs are negative for FHIT by immunostaining.
  • Aberrant methylation of the FHIT promoter occurred in a significant portion of BCCs.
  • MSP detected hypermethylation of the FHIT/FRA3B locus in nine of nine (100%) periocular BCCs and in six of eight (75%) BCCs from other body regions.
  • COBRA yielded similar results, confirming that some 88% of the 17 BCCs analysed harbour epigenetic silencing of the FHIT gene.
  • CONCLUSIONS: We have identified epigenetic silencing of the FHIT tumour suppressor gene as a frequent inactivation mechanism which is likely to contribute to functional deficiencies in DNA damage response of BCCs.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Carcinoma, Basal Cell / genetics. Gene Silencing. Genes, Tumor Suppressor. Neoplasm Proteins / genetics. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17107382.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


51. Freier K, Pungs S, Flechtenmacher C, Hofele C: [Activation of sonic hedgehog signaling in keratocystic odontogenic tumors]. HNO; 2009 Apr;57(4):345-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple basal cell carcinomas of the skin are another typical feature of Gorlin-Goltz syndrome.
  • Aberrant activation of sonic hedgehog signaling has been reported for sporadic and hereditary basal cell carcinoma caused by specific genetic mutations, but for keratocystic odontogenic tumors, the role of aberrant sonic hedgehog signaling has not yet been evaluated in detail.
  • This finding underlines the neoplastic character of this intraosseous lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] J Pathol. 2001 Aug;194(4):473-7 [11523056.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2336-40 [9192803.001]
  • [Cites] Br J Oral Maxillofac Surg. 1997 Feb;35(1):46-8 [9043004.001]
  • [Cites] J Can Dent Assoc. 2008 Mar;74(2):165-165h [18353202.001]
  • [Cites] J Mol Med (Berl). 1999 Jun;77(6):459-68 [10475061.001]
  • [Cites] Cancer. 1992 Dec 15;70(12):2988-94 [1451083.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3971-7 [14666705.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):379-83 [16487797.001]
  • [Cites] Am J Pathol. 2006 Sep;169(3):806-14 [16936257.001]
  • [Cites] J Clin Pathol. 2001 Dec;54(12):897-910 [11729208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12 ):7331-6 [12777630.001]
  • [Cites] Int J Oral Maxillofac Surg. 2004 Sep;33(6):584-92 [15308259.001]
  • [Cites] Development. 1998 Aug;125(15):2803-11 [9655803.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 Jan;10(1):1-2 [16328532.001]
  • [Cites] J Oral Pathol. 1988 Jan;17(1):39-42 [3131508.001]
  • [Cites] Pathol Int. 1999 Aug;49(8):687-94 [10504535.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10 (7):757-62 [11257109.001]
  • [Cites] Oncol Rep. 2006 May;15(5):1141-5 [16596176.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Nov;6(6):394-401 [12447651.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7 [9690244.001]
  • (PMID = 19082818.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hedgehog Proteins
  •  go-up   go-down


52. Farley RL, Manolidis S, Ratner D: Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone. Dermatol Surg; 2006 Feb;32(2):307-15; discussion 315
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive basal cell carcinoma with invasion of the parotid gland, facial nerve, and temporal bone.
  • Aggressive variants of basal cell carcinoma (BCC), such as infiltrating, morpheaform, and basosquamous types, are associated with invasion of underlying tissues and are often difficult to treat.1 BCCs located in embryonic fusion planes, such as the periauricular region, are thought to exhibit deep extension and, subsequently, high recurrence rates, although this theory has been challenged and remains controversial.2-4 Despite the known features of aggressive BCC, parotid gland invasion and temporal bone and facial nerve involvement are rarely reported occurrences.
  • We describe two patients with morpheaform BCC in the periauricular region demonstrating direct invasion of the parotid gland and concomitant facial nerve involvement.
  • These patients require complex surgical management, as highlighted in this report.
  • [MeSH-major] Bone Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Head and Neck Neoplasms / pathology. Nervous System Neoplasms / pathology. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Facial Nerve / pathology. Humans. Male. Neoplasm Invasiveness. Otorhinolaryngologic Surgical Procedures. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Temporal Bone / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16442061.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Mohammadi A, Rosa M, Rhatigan R: Eyelid basal cell carcinoma associated with solitary neurofibroma. J Cutan Pathol; 2010 Jun;37(6):707-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma associated with solitary neurofibroma.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Eyelid Neoplasms / complications. Neurofibroma / complications

  • Genetic Alliance. consumer health - Neurofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614728.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  •  go-up   go-down


5
Advertisement
4. Yamane GK: Cancer incidence in the U.S. Air Force: 1989-2002. Aviat Space Environ Med; 2006 Aug;77(8):789-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer incidence in the U.S. Air Force: 1989-2002.
  • BACKGROUND: Cancer incidence in U.S.
  • METHODS: Standardized incidence ratios (SIRs) for invasive cancer in AFAD personnel during 1989-2002 were determined using U.S. national incidence rates as the reference.
  • Cutaneous squamous and basal cell carcinomas (CAs) were excluded.
  • RESULTS: There were 2750 cases: 1986 in men and 764 in women.
  • Among men, the 10 most frequent cancers (77.6% of total) were, in descending order: melanoma; testicular CA; prostate CA; non-Hodgkin lymphoma; follicular/papillary thyroid CA; Hodgkin's Disease; colorectal CA; brain neuroepithelial CA; and (tied) bladder CA and oral squamous cell CA.
  • Among women, the 10 most frequent cancers (88.1% of total) were, in descending order: breast CA; cervical CA; follicular/papillary thyroid CA; melanoma; Hodgkin's Disease; colorectal CA;.
  • (tied) non-Hodgkin lymphoma and ovarian epithelial CA; vulvar CA; and (tied) brain neuroepithelial CA and oral squamous cell CA.
  • Compared with the U.S. population, cancer type-specific SIRs were significantly increased for cervical CA, prostate CA, and vulvar CA (range, 1.44-3.54).
  • SIRs were significantly decreased for bladder CA (men), brain neuroepithelial CA, colorectal CA (men), Hodgkin's Disease (men), non-Hodgkin lymphoma, oral squamous cell CA (men), and testicular CA (range, 0.31-0.68).
  • CONCLUSIONS: The cancer experience of the AFAD population differs substantially from that of the U.S. population.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909871.001).
  • [ISSN] 0095-6562
  • [Journal-full-title] Aviation, space, and environmental medicine
  • [ISO-abbreviation] Aviat Space Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Fan XS, Wu HY, Yu HP, Zhou Q, Zhang YF, Huang Q: Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with beta-catenin. Int J Colorectal Dis; 2010 May;25(5):583-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUNDS AND AIMS: Lgr5 is a member of the G protein receptor super-family and was shown recently to be a stem cell marker for cells with intestinal differentiation.
  • Its over-expression has been demonstrated in hepatocellular, basal cell carcinoma, and ovarian cancers but the underlying mechanisms are poorly understood.
  • METHODS: The study was carried out on a tissue microarray that consisted of 102 colorectal carcinomas (CRC; M:F = 55:47), 18 colon adenoma, and 12 colon normal mucosa cases.
  • Subsequently, expression of Lgr5 in tissue sections of tumor centre and invasive margins of 21 cases of CRC certified to be immunoreactive of Lgr5 in TMA were evaluated and possible differences of Lgr5 expression between them were analyzed.
  • RESULTS: Lgr5 immunoreactivity was observed only in single cells in the base of normal colon mucosal crypts but high in 28% (five out of 18) adenomas, and significantly higher in 54% (55/102, p = 0.016) CRC cases.
  • In normal mucosa, adenoma, and CRC, beta-catenin expression was seen in 25% (three out of 12), 27% (five out of 18), and 81% (83/102) cases, respectively, in contrast to 0, 0, and 40% (41/102) for p53 expression, respectively.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2008 Jul;213(1):52-8 [18638070.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Nature. 2007 Oct 25;449(7165):1003-7 [17934449.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):379-83 [9697701.001]
  • [Cites] Front Biosci. 2008 May 01;13:3352-63 [18508437.001]
  • [Cites] Mol Endocrinol. 1998 Dec;12(12):1830-45 [9849958.001]
  • [Cites] Hepatology. 2003 Mar;37(3):528-33 [12601349.001]
  • [Cites] Mol Endocrinol. 2000 Feb;14(2):272-84 [10674399.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 26;102(17 ):6027-32 [15837931.001]
  • [Cites] Science. 2004 Mar 12;303(5664):1684-6 [15017003.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2862-70 [18539965.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Int J Surg Pathol. 2007 Jan;15(1):38-52 [17172496.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):363-71 [16489634.001]
  • [Cites] Transl Res. 2008 Jan;151(1):10-6 [18061123.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):835-43 [18688030.001]
  • [Cites] Cell Signal. 2007 Dec;19(12):2428-33 [17651940.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] ScientificWorldJournal. 2008 Nov 23;8:1168-76 [19030762.001]
  • [Cites] Nat Genet. 2004 Oct;36(10 ):1117-21 [15378062.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2828-38 [18539961.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):387-98 [18432252.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:675-99 [17645413.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14):4042-5 [17634527.001]
  • [Cites] Annu Rev Physiol. 2009;71:241-60 [18808327.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):217-29 [17141509.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2008;73:351-6 [19478326.001]
  • [Cites] Adv Pathobiol. 1977;(6):141-52 [899956.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9736-43 [15509778.001]
  • [Cites] Cancer Biol Ther. 2006 Apr;5(4):419-26 [16575208.001]
  • [Cites] Pathobiology. 2006;73(5):213-23 [17314492.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):755-68 [18784658.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1904-9 [15790842.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3304-13 [18451157.001]
  • (PMID = 20195621.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / LGR5 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin
  •  go-up   go-down


56. Chen WL, Li JS, Yang ZH, Huang ZQ, Wang JU, Zhang B: Two submental island flaps for reconstructing oral and maxillofacial defects following cancer ablation. J Oral Maxillofac Surg; 2008 Jun;66(6):1145-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two submental island flaps for reconstructing oral and maxillofacial defects following cancer ablation.
  • PURPOSE: The purpose of this study was to assess the reliability of 2 patterns of submental island flaps--the facial-submental artery island flap and the reverse facial-submental artery island flap--used for reconstruction of oral and maxillofacial defects following cancer ablation.
  • PATIENTS AND METHODS: Thirty-eight soft tissue defects were repaired with facial-submental artery island flaps and reverse facial-submental artery island flaps following cancer surgery.
  • The primary lesions included squamous cell carcinoma of the tongue (8 cases), buccal mucosa (16), floor of the mouth (4), lower gingiva (3), oropharynx (2); recurrent squamous cell carcinoma of the palate (3); and basal cell carcinoma of the facial skin (2).
  • The clinical stage of the tumors was stage I in 5 cases, stage II in 25, and stage III in 8.
  • Facial-submental artery island flaps were used in 20 cases, reverse facial-submental artery island flaps in 18.
  • The size of the skin paddle varied from a minimum of 4 cm x 8 cm to a maximum of 5 cm x 15 cm.
  • RESULTS: The postoperative outcome for 2 patterns of submental flaps was 36 cases surviving, 2 of complete necrosis, and one other of temporary palsy of the marginal mandibular branch of the facial nerve.
  • The follow-up period was 3 to 24 months, 1 patient died of tumor local recurrences and 2 cases of cervical recurrence were observed.
  • [MeSH-major] Chin / surgery. Facial Neoplasms / surgery. Mouth Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Face / blood supply. Fatal Outcome. Female. Humans. Male. Middle Aged. Neck / blood supply. Neck / surgery. Neoplasm Staging. Oral Surgical Procedures / methods. Reconstructive Surgical Procedures / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486779.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Hanavadi S, Monypenny IJ, Mansel RE: Is mammography overused in male patients? Breast; 2006 Feb;15(1):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is no agreed protocol for the use of mammography in evaluating the male breast.
  • In order to define the role of mammography in men, we carried out a retrospective analysis of all male patients referred to the breast clinic with a history of breast lump between January 2001 and December 2003.
  • The impact of mammography in the evaluation of male breast cancer cases was studied.
  • A total of 220 male patients were referred to the breast clinic during this period.
  • Of these, 134 men had a mammographic examination, with majority (96%) being performed prior to their consultation with the breast clinician as per the clinic protocol.
  • There were 4 cases of breast cancer diagnosed during this period.
  • Breast cancer was suspected in all patients on clinical examination and was confirmed by biopsy.
  • Breast cancer in men can be suspected on clinical examination in the majority of cases.
  • One should consider imaging only those with clinically suspicious breast lumps to avoid unnecessary imaging particularly in young male patients.
  • [MeSH-major] Breast Neoplasms, Male / radiography. Mammography / utilization
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Biopsy. Breast Diseases / radiography. Child. Diagnosis, Differential. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16473746.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


58. Aoyagi S, Hata H, Homma E, Shimizu H: Controlling the histological margin for non-melanoma skin cancer conveniently using a double-bladed scalpel. J Surg Oncol; 2010 Feb 1;101(2):175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controlling the histological margin for non-melanoma skin cancer conveniently using a double-bladed scalpel.
  • BACKGROUND: In some countries, intraoperative histological evaluation to control the surgical margin for non-melanoma skin cancer is widely used instead of Mohs micrographic surgery.
  • OBJECTIVES: To evaluate the efficacy of double-bladed scalpel for intraoperative histological margin control for non-melanoma skin cancers.
  • METHODS: Between 2005 and 2009, 10 basal cell carcinomas and 5 squamous cell carcinomas were underwent complete histological margin control in which a double-bladed scalpel was used during the surgery at the Hokkaido University Hospital in Japan.
  • RESULTS: The mean number of re-excisions required for complete tumor resection was 1.4 times.
  • Nine (60%) of the 15 patients obtained histological clearance of all surgical margins at the first re-excision.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20082361.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Lally A, Bowling J: Contrasting vascular patterns: a helpful dermoscopic feature for identifying basal cell carcinoma within port wine stains. Dermatol Surg; 2010 Jun;36(6):950-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrasting vascular patterns: a helpful dermoscopic feature for identifying basal cell carcinoma within port wine stains.
  • [MeSH-major] Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Facial Neoplasms / blood supply. Port-Wine Stain / pathology. Skin Neoplasms / blood supply. Skin Neoplasms / pathology
  • [MeSH-minor] Dermoscopy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482729.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Yoo YS, Woo HY, Choi JH, Cho KR, Oh YT, Heo G: Balloon catheter assisted excision of benign cervical cyst. Auris Nasus Larynx; 2010 Aug;37(4):504-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Benign cystic masses that develop in the neck are easily excised with a wide skin incision.
  • METHODS: Two cases with a branchial cleft cyst (BCC) were removed using this method without recurrence.
  • The surgical technique includes a skin incision above the cyst, and fine dissection to expose the cyst wall.
  • The final pathological diagnosis was BCC in the two cases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20053514.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 10
  •  go-up   go-down


61. Moehrle M, Breuninger H, Schippert W, Häfner HM: Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study. Dermatol Surg; 2010 Mar;36(3):428-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter: Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular basal cell carcinomas before Mohs micrographic surgery: a randomized, double-blind, vehicle-controlled study.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Basal Cell / surgery. Mohs Surgery. Neoadjuvant Therapy. Nose Neoplasms / drug therapy. Nose Neoplasms / surgery. Skin Neoplasms / drug therapy. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Dermatol Surg. 2009 Jan;35(1):24-9 [19018814.001]
  • (PMID = 20402949.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


62. Agero AL, Busam KJ, Benvenuto-Andrade C, Scope A, Gill M, Marghoob AA, González S, Halpern AC: Reflectance confocal microscopy of pigmented basal cell carcinoma. J Am Acad Dermatol; 2006 Apr;54(4):638-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reflectance confocal microscopy of pigmented basal cell carcinoma.
  • BACKGROUND: Reflectance confocal microscopy (RCM) is a high-resolution imaging tool for in vivo noninvasive evaluation of skin lesions.
  • OBJECTIVE: We sought to describe the relevant RCM features for pigmented basal cell carcinoma (BCC).
  • METHODS: Pigmented skin lesions with a differential diagnosis of pigmented BCC were imaged using dermoscopy and RCM, followed by excision for histologic analysis.
  • LIMITATIONS: The pigmented BCCs imaged in this study were predominantly nodular; a different set or additional criteria may be necessary for detection of infiltrative and metatypical BCCs.
  • CONCLUSION: RCM may permit in vivo diagnosis of pigmented BCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Melanoma / diagnosis. Melanoma / pathology. Microscopy, Confocal. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546585.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Pisani C, Poggiali S, De Padova L, Andreassi A, Bilenchi R: Basal cell carcinoma of the vulva. J Eur Acad Dermatol Venereol; 2006 Apr;20(4):446-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the vulva.
  • Basal cell carcinoma (BCC), the most common human malignancy, accounting for 75% of all non-melanoma skin cancer, is uncommon on unexposed skin such as the perianal and genital regions.
  • We describe a woman with BCC of the vulva treated with local resection.
  • All margins of excision were free of disease.
  • Approximately 200 cases of BCC on perianal and genital skin have been reported in the literature.
  • Although the aetiology of vulvar BCC is not known, early diagnosis is important.
  • Because BCC in these sites sometimes seems innocuous, biopsy of all suspect lesions is advisable.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Vulvar Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643146.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


64. Otley CC: Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face. Arch Dermatol; 2006 Sep;142(9):1235; author reply 1235-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness of Mohs micrographic surgery vs surgical excision for basal cell carcinoma of the face.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Dermatol. 2006 Feb;142(2):187-94 [16490846.001]
  • (PMID = 16983019.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


65. Xie J: Implications of hedgehog signaling antagonists for cancer therapy. Acta Biochim Biophys Sin (Shanghai); 2008 Jul;40(7):670-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of hedgehog signaling antagonists for cancer therapy.
  • The hedgehog (Hh) pathway, initially discovered in Drosophila by two Nobel laureates, Dr.
  • Eric Wieschaus and Dr.
  • Christiane Nusslein-Volhard, is a major regulator for cell differentiation, tissue polarity and cell proliferation.
  • Studies from many laboratories, including ours, reveal activation of this pathway in most basal cell carcinomas and in approximately 30% of extracutaneous human cancers, including medulloblastomas, gastrointestinal, lung, breast and prostate cancers.
  • Even more exciting is the discovery and synthesis of specific signaling antagonists for the Hh pathway, which have significant clinical implications in novel cancer therapeutics.
  • This review discusses the major advances in the current understanding of Hh signaling activation in different types of human cancers, the molecular basis of Hh signaling activation, the major antagonists for Hh signaling inhibition and their potential clinical application in human cancer therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3161-73 [17114586.001]
  • [Cites] PLoS Biol. 2006 Jul;4(8):e232 [16895439.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1415-23 [17115028.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6442-7 [17452975.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):961-4 [18281468.001]
  • [Cites] Adv Exp Med Biol. 2008;624:241-51 [18348461.001]
  • [Cites] Curr Oncol Rep. 2008 Mar;10(2):107-13 [18377823.001]
  • [Cites] Nature. 2004 Dec 23;432(7020):1045-50 [15616566.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7186-9 [12499255.001]
  • [Cites] Dev Biol. 2003 Feb 1;254(1):1-18 [12606278.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4616-21 [12679522.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):799-812 [12791266.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Nature. 2003 Nov 6;426(6962):83-7 [14603322.001]
  • [Cites] Dev Cell. 2004 Jun;6(6):801-13 [15177029.001]
  • [Cites] J Biol. 2002 Nov 6;1(2):10 [12437772.001]
  • [Cites] Endocrinology. 2004 Aug;145(8):3961-70 [15132968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10833-8 [15249678.001]
  • [Cites] BMC Cancer. 2004 Aug 4;4:43 [15294024.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):622-6 [8757131.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Curr Biol. 1996 Mar 1;6(3):298-304 [8805249.001]
  • [Cites] Science. 1996 Oct 11;274(5285):255-9 [8824192.001]
  • [Cites] J Investig Dermatol Symp Proc. 1999 Sep;4(1):41-5 [10537006.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):312-9 [10559945.001]
  • [Cites] Development. 2000 Apr;127(8):1593-605 [10725236.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):86-90 [10894547.001]
  • [Cites] J Biol Chem. 2000 Jul 21;275(29):21856-61 [10806213.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):757-62 [11257109.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):555-8 [11340611.001]
  • [Cites] Cell. 2001 Jun 15;105(6):781-92 [11440720.001]
  • [Cites] Nature. 2001 Jul 12;412(6843):194-8 [11449277.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9255-9 [11481486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5442-7 [11960000.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Curr Biol. 2002 Jun 25;12(12):983-95 [12123571.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:47-65 [12142354.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6 [12391318.001]
  • [Cites] Nature. 2002 Oct 31;419(6910):929-34 [12410312.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):17900-7 [15598741.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):45-64 [15580285.001]
  • [Cites] Mech Dev. 2005 Feb;122(2):223-30 [15652709.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):43-51 [15656799.001]
  • [Cites] Mol Carcinog. 2005 Apr;42(4):183-92 [15754313.001]
  • [Cites] Curr Top Med Chem. 2005;5(2):147-57 [15853643.001]
  • [Cites] Breast Cancer Res. 2005;7(3):86-95 [15987436.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):7042-53 [16055716.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):7054-68 [16055717.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11325-30 [16061793.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):728-33 [15970691.001]
  • [Cites] Differentiation. 2005 Oct;73(8):397-405 [16316410.001]
  • [Cites] Development. 2006 Jan;133(1):3-14 [16339192.001]
  • [Cites] Genes Dev. 2006 Jan 1;20(1):22-7 [16357211.001]
  • [Cites] J Biol Chem. 2006 Jan 6;281(1):9-12 [16293631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):33-8 [16371461.001]
  • [Cites] Genes Dev. 2006 Feb 1;20(3):276-81 [16421275.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):177-86 [16459297.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] Hum Mutat. 2006 Mar;27(3):215-9 [16419085.001]
  • [Cites] Cancer Biol Ther. 2006 Jan;5(1):111-7 [16397407.001]
  • [Cites] Carcinogenesis. 2006 Apr;27(4):748-57 [16339184.001]
  • [Cites] Pancreas. 2006 Mar;32(2):119-29 [16552330.001]
  • [Cites] Future Oncol. 2005 Jun;1(3):331-8 [16556007.001]
  • [Cites] Mol Cell Biol. 2006 May;26(9):3365-77 [16611981.001]
  • [Cites] Cell. 2006 Apr 21;125(2):343-57 [16630821.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3764-72 [16648472.001]
  • [Cites] Cell. 2006 May 5;125(3):439-42 [16678091.001]
  • [Cites] Dev Cell. 2006 May;10(5):657-65 [16647303.001]
  • [Cites] Dev Cell. 2006 May;10(5):647-56 [16647304.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6063-71 [16778178.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1334-40 [16501253.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):3965-9 [16810741.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):14-29 [16831586.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] Cancer Biol Ther. 2006 Jun;5(6):674-83 [16855373.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6283-98 [16880536.001]
  • [Cites] Mol Cell Biol. 2006 Sep;26(17):6609-22 [16914743.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Nat Rev Genet. 2006 Nov;7(11):841-50 [17047684.001]
  • [Cites] Gene Ther. 2006 Nov;13(22):1587-94 [16826192.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):369-73 [17086203.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):407-13 [8837770.001]
  • [Cites] Nature. 1996 Nov 14;384(6605):129-34 [8906787.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Development. 1997 Apr;124(7):1313-22 [9118802.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1798-803 [9581815.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Nature. 1998 Jul 2;394(6688):85-8 [9665133.001]
  • [Cites] Nat Genet. 1998 Sep;20(1):54-7 [9731531.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):833-6 [9989836.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):617-21 [10050855.001]
  • [Cites] Genes Dev. 1999 Aug 15;13(16):2072-86 [10465785.001]
  • [Cites] Genes Dev. 1999 Sep 15;13(18):2375-87 [10500095.001]
  • [Cites] Development. 1999 Nov;126(21):4873-84 [10518503.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] N Engl J Med. 1960 May 5;262:908-12 [13851319.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Nature. 2005 Oct 13;437(7061):1018-21 [16136078.001]
  • [Cites] PLoS Genet. 2005 Oct;1(4):e53 [16254602.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Dev Biol. 2005 Nov 15;287(2):378-89 [16229832.001]
  • [Cites] Oncology. 2006;70(5):378-89 [17179732.001]
  • [Cites] Mol Cancer. 2006;5:74 [17173689.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Semin Liver Dis. 2007 Feb;27(1):55-76 [17295177.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2187-96 [17332349.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1389-98 [17332280.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4048-53 [17360475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5103-8 [17372229.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):1010-7 [17373734.001]
  • [Cites] Oncol Rep. 2007 May;17(5):1051-5 [17390043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5895-900 [17392427.001]
  • [Cites] Pancreas. 2007 Apr;34(3):340-6 [17414057.001]
  • [Cites] Genes Dev. 2007 May 15;21(10):1231-43 [17504940.001]
  • [Cites] Genes Dev. 2007 May 15;21(10):1244-57 [17504941.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60 [17494766.001]
  • [Cites] J Clin Invest. 2007 Jun;117(6):1575-84 [17525797.001]
  • [Cites] Cell Cycle. 2006 Nov 1;5(21):2457-63 [17102630.001]
  • [Cites] Nat Med. 2007 Aug;13(8):944-51 [17632527.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5752-61 [17353902.001]
  • [Cites] Breast Cancer Res Treat. 2007 Oct;105(2):139-55 [17295047.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7545-52 [15492281.001]
  • [Cites] Nature. 1980 Oct 30;287(5785):795-801 [6776413.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Nature. 1988 Mar 24;332(6162):371-4 [2832761.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3104-13 [2850480.001]
  • [Cites] Mol Cell Biol. 1990 Feb;10(2):634-42 [2105456.001]
  • [Cites] Cell. 1992 Apr 3;69(1):111-7 [1348213.001]
  • [Cites] Am J Med Genet. 1993 May 15;46(3):317-34 [8488879.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1401-16 [8269518.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1417-30 [7916661.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1431-44 [8269519.001]
  • [Cites] Cell. 1994 Feb 25;76(4):761-75 [8124714.001]
  • [Cites] Science. 1994 Dec 2;266(5190):1528-37 [7985023.001]
  • [Cites] Nature. 1995 Mar 23;374(6520):363-6 [7885476.001]
  • [Cites] Development. 1994 Nov;120(11):3339-53 [7720571.001]
  • [Cites] Genes Dev. 1996 Feb 1;10(3):301-12 [8595881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1571-6 [8643673.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • (PMID = 18604459.001).
  • [ISSN] 1745-7270
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094160; United States / NCI NIH HHS / CA / R01 CA094160-06A2; United States / NCI NIH HHS / CA / CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hedgehog Proteins
  • [Number-of-references] 149
  • [Other-IDs] NLM/ NIHMS56053; NLM/ PMC2515624
  •  go-up   go-down


66. Taneja S, Evans AJ, Rakha EA, Green AR, Ball G, Ellis IO: The mammographic correlations of a new immunohistochemical classification of invasive breast cancer. Clin Radiol; 2008 Nov;63(11):1228-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The mammographic correlations of a new immunohistochemical classification of invasive breast cancer.
  • AIM: Recent protein expression profiling of breast cancer has identified specific subtypes with clinical, biological, and therapeutic implications.
  • The aim of this study was to identify the mammographic correlates of these novel molecular classes of invasive breast cancer.
  • MATERIALS AND METHODS: The mammographic findings of 415 patients with operable breast cancer were correlated with the previously described protein expression classes identified by our group using immunohistochemical (IHC) assessment of a large series of breast cancer cases prepared as tissue microarrays (TMAs).
  • Twenty-five proteins of known relevance in breast cancer were assessed, including hormone receptors, HER-2 status, basal and luminal markers, p53 expression, and E-cadherin.
  • Groups characterized by HER-2 overexpression, basal characteristics, and E-cadherin positivity had a significantly higher proportion of ill-defined masses.
  • CONCLUSION: The mammographic features of breast cancer show significant correlation with molecular classes of invasive breast cancer identified by protein expression IHC analysis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. Breast Neoplasms / radiography
  • [MeSH-minor] Adult. Aged. Cadherins / metabolism. Female. Humans. Lymphatic Metastasis. Mammography. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / metabolism. Receptor, ErbB-2 / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism


67. Rollison DE, Giuliano AR, Sellers TA, Laronga C, Sweeney C, Risendal B, Baumgartner KB, Byers T, Slattery ML: Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states. Am J Epidemiol; 2008 Feb 15;167(4):447-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Population-based case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic White women living in US southwestern states.
  • Diabetes mellitus has been associated with breast cancer, although no studies appear to have adequately assessed the association in Hispanic women, a population with a high prevalence of diabetes.
  • The authors investigated this association in a population-based case-control study of Hispanic and non-Hispanic White women living in the southwestern United States.
  • Breast cancer cases diagnosed in 1999-2004 were identified through state cancer registries (1,526 non-Hispanic Whites, 798 Hispanics).
  • Having any type of diabetes was not associated with breast cancer overall (odds ratio = 0.94, 95% confidence interval: 0.78, 1.12).
  • Type 2 diabetes was observed among 19% of Hispanics and 9% of non-Hispanic Whites but was not associated with breast cancer in either group.
  • Gestational diabetes was inversely associated with breast cancer in both ethnic groups, especially when first diagnosed at age < or =35 years (odds ratio = 0.54, 95% confidence interval: 0.37, 0.79).
  • In this study, diabetes was not associated with breast cancer overall, although the inverse association with gestational diabetes warrants further investigation.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Hispanic American Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes Care. 2003 Apr;26(4):1047-51 [12663571.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):129-35 [17476589.001]
  • [Cites] Int J Epidemiol. 1999 Oct;28(5):816-23 [10597976.001]
  • [Cites] J Natl Cancer Inst. 1970 Mar;44(3):673-86 [11515436.001]
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):875-80 [11808705.001]
  • [Cites] Am J Epidemiol. 2002 Aug 15;156(4):349-52 [12181105.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):149-55 [14692035.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):267-75 [15090721.001]
  • [Cites] Diabetes Care. 2004 May;27(5):1194-9 [15111544.001]
  • [Cites] Am J Epidemiol. 2004 Jun 15;159(12):1160-7 [15191933.001]
  • [Cites] Int J Cancer. 1974 Aug 15;14(2):153-60 [4378317.001]
  • [Cites] J Chronic Dis. 1982;35(1):13-9 [7068798.001]
  • [Cites] J Chronic Dis. 1985;38(5):435-41 [3998058.001]
  • [Cites] Diabetes Metab Rev. 1990 Feb;6(1):29-45 [2192854.001]
  • [Cites] Eur J Cancer. 1990;26(7):781-5 [2145895.001]
  • [Cites] Int J Gynaecol Obstet. 1991 May;35(1):13-8 [1680070.001]
  • [Cites] Diabetes Care. 1991 Jul;14(7):695-705 [1914821.001]
  • [Cites] Am J Epidemiol. 1992 May 1;135(9):965-73 [1595695.001]
  • [Cites] Epidemiology. 1994 Jan;5(1):102-8 [8117767.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Dec;4(8):807-11 [8634649.001]
  • [Cites] Prev Med. 1997 Jan-Feb;26(1):144-53 [9010910.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):360-3 [9139868.001]
  • [Cites] Br J Cancer. 1997;75(11):1699-703 [9184190.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1360-5 [9308706.001]
  • [Cites] Lancet. 1998 May 9;351(9113):1393-6 [9593409.001]
  • [Cites] Diabetes. 1998 Aug;47(8):1302-10 [9703332.001]
  • [Cites] Am J Epidemiol. 1998 Oct 1;148(7):683-92 [9778175.001]
  • [Cites] Epidemiology. 1998 Nov;9(6):641-7 [9799175.001]
  • [Cites] J Intern Med. 1997 Jun;241(6):471-5 [10497622.001]
  • [Cites] JAMA. 2005 Jan 12;293(2):194-202 [15644546.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):439-48 [15770008.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):2070-5 [15886700.001]
  • [Cites] Diabetes Care. 2006 Jun;29(6):1263-8 [16732006.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):253-9 [16839219.001]
  • [Cites] Breast Cancer Res Treat. 2006 Aug;98(3):349-56 [16541321.001]
  • [Cites] Arch Intern Med. 2006 Sep 25;166(17):1871-7 [17000944.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):142-50 [17220343.001]
  • [Cites] Cancer Causes Control. 2007 Jun;18(5):505-15 [17437179.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):856-62 [17397032.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):85-101 [17080310.001]
  • [Cites] Carcinogenesis. 2007 Jul;28(7):1561-6 [17440036.001]
  • [Cites] Breast Cancer Res Treat. 2007 Aug;104(2):197-209 [17051426.001]
  • [Cites] Diabetes Care. 2003 Jun;26(6):1752-8 [12766105.001]
  • (PMID = 18033764.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA078682-07; United States / NCI NIH HHS / CA / CA078682; United States / NCI NIH HHS / CA / R01 CA078552; United States / NCI NIH HHS / CA / R01 CA078762; United States / NCI NIH HHS / CA / CA078682-07; United States / NCI NIH HHS / CA / R01 CA078802; United States / NCI NIH HHS / CA / R01 CA078682; United States / NCI NIH HHS / CA / CA078552; United States / NCI NIH HHS / PC / N01-PC-67000; United States / NCI NIH HHS / CA / CA078762; United States / NCI NIH HHS / CA / CA078802
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS50878; NLM/ PMC2925515
  •  go-up   go-down


68. Centers for Disease Control and Prevention (CDC): Decline in breast cancer incidence--United States, 1999-2003. MMWR Morb Mortal Wkly Rep; 2007 Jun 8;56(22):549-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decline in breast cancer incidence--United States, 1999-2003.
  • Breast cancer is the most commonly diagnosed cancer among females in the United States.
  • The 2006 Annual Report to the Nation on the Status of Cancer described a stabilization in female breast cancer incidence rates during 2001-2003, ending increases that began in the 1980s, and a decline in the number of breast cancer cases diagnosed in 2003.
  • In addition, researchers who used 1990-2003 data from the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) program, representing approximately 14% of the U.S. population, reported a 7% decrease in invasive breast cancer rates from 2002 to 2003.
  • To further assess breast cancer annual incidence rates during 1999-2003, CDC analyzed data collected by CDC's National Program of Cancer Registries (NPCR) and the NCI SEER program.
  • The results of this analysis indicated that age-adjusted incidence rates for invasive breast cancer decreased each year during 1999-2003, with the greatest decrease (6.1%) occurring from 2002 to 2003; women aged > or = 50 years experienced a significant decrease during this period.
  • Rates of in situ (i.e., noninvasive) breast cancer increased each year during 1999-2002 and then decreased from 2002 to 2003; women aged 50-79 years experienced a significant decrease during this period.
  • [MeSH-major] Breast Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17557070.001).
  • [ISSN] 1545-861X
  • [Journal-full-title] MMWR. Morbidity and mortality weekly report
  • [ISO-abbreviation] MMWR Morb. Mortal. Wkly. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Sellers TA, Jensen LE, Vierkant RA, Fredericksen ZS, Brandt KR, Giuliano AR, Pankratz VS, Cerhan JR, Vachon CM: Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study. Cancer Causes Control; 2007 Jun;18(5):505-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study.
  • Data from the Minnesota Breast Cancer Family Study cohort (n=6,130 women) were used to examine the association of type II diabetes with mammographic percent density and incident breast cancer (BC).
  • The first set of analyses evaluated diabetes (DM) as a risk factor for breast cancer.
  • A total of 403 women (6.6%) reported a diagnosis of type II diabetes and 333 women reported an incident breast cancer.
  • Women who reported type II diabetes had an age-adjusted relative risk (RR) for breast cancer of 1.44 (95% CI 0.89-2.32) compared to those who did not.
  • Breast cancer cases with diabetes did not have a significantly higher percent density than cases without diabetes.
  • Our findings suggest that breast cancer risk may be increased among women with type II diabetes, but that type II diabetes does not significantly influence mammographic breast density.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / epidemiology. Diabetes Mellitus, Type 2 / epidemiology. Mammography


70. Rajadhyaksha M: Confocal microscopy of skin cancers: translational advances toward clinical utility. Conf Proc IEEE Eng Med Biol Soc; 2009;2009:3231-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal microscopy of skin cancers: translational advances toward clinical utility.
  • Recent advances in translational research in and technology for confocal microscopy of skin cancers, toward clinical applications, are described.
  • Advances in translational research are in diagnosis of melanoma in vivo, pre-operative mapping of lentigo maligna melanoma margins to guide surgery and intra-operative imaging of residual basal cell carcinomas to guide shave-biopsy.
  • Advances in technology include mosaicing microscopy for detection of basal cell carcinomas in large areas of excised tissue, toward rapid pathology-at-the-bedside, and development of small, simple and low-cost line-scanning confocal microscopes for worldwide use in diverse primary healthcare settings.
  • [MeSH-major] Microscopy, Confocal / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Algorithms. Biopsy. Dermatology / instrumentation. Dermatology / methods. Dermoscopy / methods. Equipment Design. Humans. Hutchinson's Melanotic Freckle / diagnosis. Hutchinson's Melanotic Freckle / pathology. Melanoma / diagnosis. Melanoma / pathology. Reproducibility of Results. Sensitivity and Specificity. Ultraviolet Rays

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Opt. 2007 Apr 1;46(10):1843-51 [17356629.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):644-58 [17630045.001]
  • [Cites] J Invest Dermatol. 2007 Dec;127(12):2759-65 [17657243.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Invest Dermatol. 2009 Jan;129(1):131-8 [18633444.001]
  • [Cites] J Microsc. 2009 Jan;233(1):149-59 [19196421.001]
  • [Cites] Opt Lett. 2006 Apr 1;31(7):942-4 [16599219.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034012 [19566305.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034050 [19566342.001]
  • [Cites] Arch Dermatol. 2001 Jul;137(7):923-9 [11453812.001]
  • [Cites] J Am Acad Dermatol. 2004 Dec;51(6):923-30 [15583584.001]
  • [Cites] Br J Dermatol. 2005 Nov;153(5):1031-6 [16225620.001]
  • [Cites] Br J Dermatol. 2009 Jun;160(6):1242-50 [19416248.001]
  • (PMID = 19964286.001).
  • [ISSN] 1557-170X
  • [Journal-full-title] Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
  • [ISO-abbreviation] Conf Proc IEEE Eng Med Biol Soc
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB002715; United States / NIBIB NIH HHS / EB / R01EB002715; United States / NCI NIH HHS / CA / R43 CA093106; United States / NIBIB NIH HHS / EB / R01EB006947; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / R44 CA093106; United States / NIBIB NIH HHS / EB / R01 EB006947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS582452; NLM/ PMC4040219
  •  go-up   go-down


71. Aulmann C, Seufert P, Sandherr M, Schlimok G, Schulze R, Oruzio D: [A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis]. Internist (Berl); 2007 Sep;48(9):1015-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A 65-year-old female patient with breast cancer accompanied by thrombocytopenia and hyperfibrinolysis].
  • Low platelet counts and hyperfibrinolysis led to the diagnosis of recurrent breast cancer in this case.
  • A tumour disease with disturbed hemostasis caused by both plasmatic coagulation and thrombocytopenia has not yet been reported.
  • [MeSH-major] Breast Neoplasms / complications. Breast Neoplasms / diagnosis. Fibrinolysis. Hemorrhagic Disorders / complications. Hemorrhagic Disorders / diagnosis. Thrombocytopenia / complications. Thrombocytopenia / diagnosis
  • [MeSH-minor] Aged. Female. Humans. Paraneoplastic Syndromes / complications. Paraneoplastic Syndromes / diagnosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1999 Aug;22(4):411-3 [10440202.001]
  • [Cites] South Med J. 2002 Nov;95(11):1335-7 [12540004.001]
  • [Cites] Thromb Haemost. 2001 Sep;86(3):828-33 [11583315.001]
  • [Cites] Am J Clin Pathol. 1979 Jan;71(1):10-6 [420161.001]
  • [Cites] Am J Clin Oncol. 2000 Feb;23(1):74-7 [10683084.001]
  • [Cites] Respir Med. 2004 Feb;98(2):93-8 [14971870.001]
  • [Cites] Semin Thromb Hemost. 1996;22(6):459-78 [9122711.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(10):555-9 [9393589.001]
  • [Cites] Jpn J Clin Oncol. 2001 Aug;31(8):388-94 [11574632.001]
  • [Cites] N Engl J Med. 1994 Nov 3;331(18):1207-11 [7935660.001]
  • [Cites] Blood Coagul Fibrinolysis. 2004 Jan;15(1):9-13 [15166937.001]
  • (PMID = 17704902.001).
  • [ISSN] 0020-9554
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW: Histology-based treatment of basal cell carcinoma. Acta Derm Venereol; 2009;89(5):454-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-based treatment of basal cell carcinoma.
  • Basal cell carcinoma is the most common type of skin cancer and its incidence is still rising.
  • Selection criteria were histological subtype, primary or recurrent basal cell carcinoma and tumour localization.
  • Although surgery remains the preferred treatment for most basal cell carcinomas, patient and tumour characteristics should be taken into account when choosing the most suitable treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Cryotherapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Evidence-Based Medicine. Humans. Neoplasm Invasiveness. Patient Selection. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2009;89(5):450-2 [19734965.001]
  • [ErratumIn] Acta Derm Venereol. 2009 Nov;89(6):667
  • (PMID = 19734968.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


73. Megehee JA, Hosler JP, Lundrigan MD: Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of Mycobacterium smegmatis. Microbiology; 2006 Mar;152(Pt 3):823-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of Mycobacterium smegmatis.
  • Spectroscopic analysis of membranes isolated from Mycobacterium smegmatis, along with analysis of its genome, indicates that the cytochrome c branch of its respiratory pathway consists of a modified bc1 complex that contains two cytochromes c in its c1 subunit, similar to other acid-fast bacteria, and an aa3-type cytochrome c oxidase.
  • A functional association of the cytochrome bcc and aa3 complexes was indicated by the findings that levels of detergent sufficient to completely disrupt isolated membranes failed to inhibit quinol-driven O2 reduction, but known inhibitors of the bc1 complex did inhibit quinol-driven O2 reduction.
  • However, high concentrations of monovalent salts had no effect on O2 reduction, suggesting that ionic interactions between extramembrane domains do not play the major role in stabilizing the bcc-aa3 interaction.
  • The results indicate that hydrophobic interactions are the primary forces maintaining the bcc-aa3 interaction, but ionic interactions may assist in aligning the two complexes for efficient electron transfer.
  • [MeSH-major] Electron Transport Complex III / metabolism. Electron Transport Complex IV / metabolism. Mycobacterium smegmatis / physiology
  • [MeSH-minor] Cell Membrane / enzymology. Electron Transport. Hydrophobic and Hydrophilic Interactions. Oxygen Consumption

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514162.001).
  • [ISSN] 1350-0872
  • [Journal-full-title] Microbiology (Reading, England)
  • [ISO-abbreviation] Microbiology (Reading, Engl.)
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM56824
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.10.2.2 / Electron Transport Complex III; EC 1.9.3.1 / Electron Transport Complex IV
  •  go-up   go-down


74. Jahagirdar SS, Thakre TP, Kale SM, Kulkarni H, Mamtani M: A clinicopathological study of eyelid malignancies from central India. Indian J Ophthalmol; 2007 Mar-Apr;55(2):109-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment depends on the invasiveness of the cancer which in turn depends on the type of malignancy.
  • MATERIALS AND METHODS: We report a series of 27 cases of eyelid malignancies.
  • In the same case series, we also include a case of malignant hemangiopericytoma which is an extremely rare form of eyelid malignancy worldwide.
  • RESULTS: We observed that sebaceous cell carcinoma (approximately 37%) was almost as prevalent as basal cell carcinoma (approximately 44%) in the study subjects and had an earlier age of occurrence and a more rapid clinical course.
  • CONCLUSIONS: Sebaceous cell carcinoma of the eyelid is almost as common as basal cell carcinoma in a large tertiary care centre in central India.
  • [MeSH-minor] Adenocarcinoma, Sebaceous / epidemiology. Adenocarcinoma, Sebaceous / pathology. Adenocarcinoma, Sebaceous / surgery. Biopsy, Fine-Needle. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Diagnosis, Differential. Female. Hemangiopericytoma / epidemiology. Hemangiopericytoma / pathology. Hemangiopericytoma / surgery. Humans. India / epidemiology. Male. Middle Aged. Neoplasm Staging. Ophthalmologic Surgical Procedures / methods. Prevalence. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322599.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


75. Zarineh A, Kozovska ME, Brown WG, Elder DE, Rabkin MS: Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature. J Cutan Pathol; 2008 Oct;35 Suppl 1:83-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature.
  • Unlike a recently reported case of SMH combined with a melanocytic nevus and basal cell carcinoma, the current lesion did not occur in association with a Becker's nevus.
  • [MeSH-minor] Actins / metabolism. Antigens, Neoplasm / metabolism. Calmodulin-Binding Proteins / metabolism. Humans. Immunohistochemistry. MART-1 Antigen. Male. Melanoma-Specific Antigens. Middle Aged. Neoplasm Proteins / metabolism

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544054.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, Neoplasm; 0 / Calmodulin-Binding Proteins; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


76. Kolár Z, Geierová M, Bouchal J, Pazdera J, Zboril V, Tvrdý P: Immunohistochemical analysis of the biological potential of odontogenic keratocysts. J Oral Pathol Med; 2006 Feb;35(2):75-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Nevoid basal cell carcinoma syndrome (NBCCS) keratocysts were characterized by higher expression of Bcl-2, p27Kip1 and c-erbB-2 as well as by lower proliferative activity measured by Ki-67 in basal cell epithelium and by a lower inflammatory response in comparison with sporadic keratocysts.
  • Dentigerous, radicular and non-specified odontogenic cysts differed from both NBCCS and sporadic keratocysts in a wide spectrum of apoptosis and/or cell cycle-related protein expressions, higher proliferation in the basal cell layer, and vice versa, lower proliferation in the suprabasal cell layer.
  • [MeSH-minor] Apoptosis / physiology. Apoptosis Regulatory Proteins / analysis. Basal Cell Nevus Syndrome / metabolism. Basal Cell Nevus Syndrome / pathology. Biology. Biomarkers / analysis. Cell Cycle Proteins / analysis. Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Dentigerous Cyst / chemistry. Dentigerous Cyst / pathology. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / analysis. Prognosis. Protein Kinase Inhibitors / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Radicular Cyst / chemistry. Radicular Cyst / pathology. Receptor, ErbB-2 / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430736.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers; 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


77. Thievessen I, Wolter M, Prior A, Seifert HH, Schulz WA: Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines. J Cell Physiol; 2005 May;203(2):372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling in normal urothelial cells and in urothelial carcinoma cell lines.
  • Constitutive activation of hedgehog signaling, often caused by PTCH1 inactivation and leading to inappropriate activation of GLI target genes, is crucial for the development of several human tumors including basal cell carcinoma of the skin and medulloblastoma.
  • The PTCH1 gene at 9q22 is also considered as a candidate tumor suppressor in transitional cell carcinoma (TCC), of which >50% show LOH in this region.
  • We have therefore investigated GLI-dependent promoter activity and expression of hedgehog pathway components in TCC cell lines and proliferating normal urothelial cells.
  • [MeSH-major] Carcinoma, Transitional Cell / metabolism. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Neoplastic / physiology. Signal Transduction / physiology. Trans-Activators / metabolism. Urinary Bladder Neoplasms / metabolism. Urothelium / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Genes, Tumor Suppressor. Hedgehog Proteins. Humans. Membrane Proteins / genetics. Membrane Proteins / metabolism. Promoter Regions, Genetic / genetics. RNA, Messenger / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism. Veratrum Alkaloids / pharmacology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15521068.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Veratrum Alkaloids; 0 / patched receptors; ZH658AJ192 / cyclopamine
  •  go-up   go-down


78. Turkovic L, Gurrin LC, Bahlo M, Dite GS, Southey MC, Hopper JL: Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age. BMC Cancer; 2010;10:466
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
  • BACKGROUND: BRCA1 and BRCA2 mutations are found in a proportion of families with multiple early-onset breast cancers.
  • METHODS: DNA sequence data for BRCA1 and BRCA2 was obtained from 571 participants from the Australian Breast Cancer Family Study.
  • CONCLUSIONS: We observed differences in the frequency of common genetic variants of the BRCA1 and BRCA2 and their haplotypes between early-onset breast cancer cases who did and did not carry deleterious mutations in these genes.
  • [MeSH-major] BRCA1 Protein / genetics. BRCA2 Protein / genetics. Breast Neoplasms / genetics. Genetic Predisposition to Disease. Germ-Line Mutation / genetics. Haplotypes / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Adolescent. Adult. Australia. Case-Control Studies. Female. Founder Effect. Humans. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Res. 2001 Jan;11(1):143-51 [11156623.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(2):379-86 [18704680.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] Hum Mutat. 2002 Jul;20(1):65-73 [12112659.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):448-57 [12644538.001]
  • [Cites] Eur J Hum Genet. 2003 Jun;11(6):489-92 [12774043.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]
  • [Cites] Am J Hum Genet. 2004 Jul;75(1):35-43 [15148658.001]
  • [Cites] Hum Mol Genet. 2004 Oct 15;13(20):2431-41 [15317758.001]
  • [Cites] Hum Mol Genet. 1997 Feb;6(2):285-9 [9063749.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 1;90(7):532-6 [9539249.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R171-5 [15743496.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7516-22 [16103107.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • (PMID = 20807450.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA1 protein, human; 0 / BRCA2 Protein; 0 / BRCA2 protein, human
  • [Other-IDs] NLM/ PMC2940805
  •  go-up   go-down


79. Silva Idos S, De Stavola B, McCormack V, Collaborative Group on Pre-Natal Risk Factors and Subsequent Risk of Breast Cancer: Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies. PLoS Med; 2008 Sep 30;5(9):e193
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birth size and breast cancer risk: re-analysis of individual participant data from 32 studies.
  • BACKGROUND: Birth size, perhaps a proxy for prenatal environment, might be a correlate of subsequent breast cancer risk, but findings from epidemiological studies have been inconsistent.
  • We re-analysed individual participant data from published and unpublished studies to obtain more precise estimates of the magnitude and shape of the birth size-breast cancer association.
  • Individual participant data from 32 studies, comprising 22,058 breast cancer cases, were obtained.
  • Birth weight was positively associated with breast cancer risk in studies based on birth records (pooled relative risk [RR] per one standard deviation [SD] [= 0.5 kg] increment in birth weight: 1.06; 95% confidence interval [CI] 1.02-1.09) and parental recall when the participants were children (1.02; 95% CI 0.99-1.05), but not in those based on adult self-reports, or maternal recall during the woman's adulthood (0.98; 95% CI 0.95-1.01) (p for heterogeneity between data sources = 0.003).
  • Birth length and head circumference from birth records were also positively associated with breast cancer risk (pooled RR per one SD increment: 1.06 [95% CI 1.03-1.10] and 1.09 [95% CI 1.03-1.15], respectively).
  • The birth size effects did not appear to be confounded or mediated by established breast cancer risk factors and were not modified by age or menopausal status.
  • The cumulative incidence of breast cancer per 100 women by age 80 y in the study populations was estimated to be 10.0, 10.0, 10.4, and 11.5 in those who were, respectively, in the bottom, second, third, and top fourths of the birth length distribution.
  • CONCLUSIONS: This pooled analysis of individual participant data is consistent with birth size, and in particular birth length, being an independent correlate of breast cancer risk in adulthood.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Birth Weight.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1664-6 [14583767.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):997-1000 [14601061.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1666-8 [15477861.001]
  • [Cites] Br J Cancer. 1988 Apr;57(4):437-9 [3390382.001]
  • [Cites] Lancet. 1990 Apr 21;335(8695):939-40 [1970028.001]
  • [Cites] Lancet. 1992 Oct 24;340(8826):1015-8 [1357410.001]
  • [Cites] Biometrics. 1992 Sep;48(3):795-806 [1420842.001]
  • [Cites] Epidemiology. 1996 Jan;7(1):34-7 [8664398.001]
  • [Cites] Lancet. 1996 Dec 7;348(9041):1542-6 [8950880.001]
  • [Cites] J Natl Cancer Inst. 1997 Jan 1;89(1):71-6 [8978409.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1997 May;24(5):497-505 [9161941.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3281-4 [9329354.001]
  • [Cites] Paediatr Perinat Epidemiol. 1998 Oct;12(4):397-407 [9805713.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):1145-8 [10084609.001]
  • [Cites] Am J Epidemiol. 1999 Apr 15;149(8):726-9 [10206622.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):85-94 [10334647.001]
  • [Cites] Pediatr Nurs. 1999 Jan-Feb;25(1):13-7 [10335245.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R656-67 [15535848.001]
  • [Cites] Int J Cancer. 2005 Apr 10;114(3):461-4 [15551343.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):611-7 [15700315.001]
  • [Cites] Diabetologia. 2005 Sep;48(9):1736-42 [16052327.001]
  • [Cites] Cancer Causes Control. 2006 May;17(4):395-401 [16596291.001]
  • [Cites] Am J Epidemiol. 2006 Jun 1;163(11):1053-64 [16624970.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1734-7 [16641898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1469-72 [16896034.001]
  • [Cites] Obesity (Silver Spring). 2006 Jul;14(7):1257-63 [16899807.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2136-41 [16804898.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2007-25 [16823839.001]
  • [Cites] Trends Endocrinol Metab. 2006 Nov;17(9):340-8 [16997567.001]
  • [Cites] Carcinogenesis. 2006 Dec;27(12):2464-8 [16777984.001]
  • [Cites] Breast Cancer Res. 2007;9(3):R29 [17501995.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):481-5 [18022897.001]
  • [Cites] Lancet Oncol. 2007 Dec;8(12):1088-100 [18054879.001]
  • [Cites] Epidemiology. 2008 Mar;19(2):197-203 [18300695.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R8 [18205956.001]
  • [Cites] Pediatr Res. 1999 Nov;46(5):491-5 [10541308.001]
  • [Cites] Epidemiology. 2000 May;11(3):315-9 [10784250.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):840-1 [10814680.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):964-8 [10970703.001]
  • [Cites] Am J Epidemiol. 2000 Sep 15;152(6):514-27 [10997541.001]
  • [Cites] J Natl Cancer Inst. 2001 Jan 3;93(1):60-2 [11136844.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):248-51 [11146453.001]
  • [Cites] Am J Epidemiol. 2000 Dec 15;152(12):1121-8 [11130617.001]
  • [Cites] Br J Cancer. 2001 May 4;84(9):1193-8 [11336470.001]
  • [Cites] Stat Med. 2001 Jul 30;20(14):2115-30 [11439425.001]
  • [Cites] Acta Obstet Gynecol Scand. 2001 Oct;80(10):931-6 [11580738.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1680-4 [11742488.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):84-8 [11857016.001]
  • [Cites] Br J Cancer. 2002 Jan 7;86(1):89-91 [11857017.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):207-10 [11867509.001]
  • [Cites] Pediatrics. 2002 Jun;109(6):1131-5 [12042554.001]
  • [Cites] Semin Perinatol. 2002 Aug;26(4):260-7 [12211616.001]
  • [Cites] Br J Cancer. 2002 Nov 18;87(11):1234-45 [12439712.001]
  • [Cites] Am J Epidemiol. 2003 Feb 1;157(3):258-66 [12543626.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5656-60 [14671149.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):519-24 [15266328.001]
  • [Cites] Obstet Gynecol. 2004 Oct;104(4):671-7 [15458884.001]
  • [Cites] Obstet Gynecol. 2004 Oct;104(4):720-6 [15458892.001]
  • [Cites] N Engl J Med. 2004 Oct 14;351(16):1619-26 [15483280.001]
  • [Cites] BMJ. 2003 Feb 1;326(7383):248 [12560272.001]
  • [Cites] Breast Cancer Res. 2003;5(1):42-4 [12559045.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):61-4 [12708726.001]
  • [Cites] Cancer Causes Control. 2003 May;14(4):347-55 [12846366.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Sep;12(9):860-5 [14504195.001]
  • [CommentIn] PLoS Med. 2008 Sep 30;5(9):e194 [18828668.001]
  • (PMID = 18828667.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / C14292/A5609; United Kingdom / Cancer Research UK / / C150/A5660
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2553821
  •  go-up   go-down


80. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE: Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst; 2006 Oct 4;98(19):1406-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women.
  • BACKGROUND: Higher levels of endogenous sex steroid hormones are associated with increased risks of breast cancer in postmenopausal women.
  • We prospectively evaluated associations between plasma sex hormone levels and breast cancer risk among premenopausal women in a case-control study nested within the Nurses' Health Study II.
  • A total of 197 cases of breast cancer were diagnosed among these women after blood collection and before June 1, 2003; these case subjects were matched to 394 control subjects.
  • Logistic regression models, controlling for breast cancer risk factors, were used to calculate relative risks (RRs) and 95% confidence intervals (CIs).
  • RESULTS: Women in the highest (versus the lowest) quartiles of follicular total and free estradiol levels had statistically significantly increased risks of breast cancer (RR = 2.1 [95% CI = 1.1 to 4.1], P(trend) = .08, and RR = 2.4 [95% CI = 1.3 to 4.5], P(trend) = .01, respectively); the associations were stronger for invasive breast cancer and for estrogen and progesterone receptor-positive (ER+/PR+) tumors.
  • Luteal estradiol levels were not associated with breast cancer risk.
  • Higher levels of total and free testosterone and androstenedione in both menstrual cycle phases were associated with modest, non-statistically significant increases in overall risk of breast cancer and with stronger, statistically significant increases in risks of invasive and ER+/PR+ cancers (e.g., RR of invasive cancers for the top [versus bottom] quartile of luteal total testosterone levels = 2.0 [95% CI = 1.1 to 3.6], P(trend) = .05, and RR of ER+/PR+ cancers = 2.9 [95% CI = 1.4 to 6.0], P(trend) = .02).
  • Levels of estrone, estrone sulfate, progesterone, and sex hormone-binding globulin were not associated with breast cancer risk.
  • The absolute number of cases observed over 3 years were 30 among women in the lowest 25% of follicular total estradiol levels and 50 among women in the highest 25%.
  • CONCLUSIONS: Levels of circulating estrogens and androgens may be important in the etiology of premenopausal breast cancer.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / metabolism. Gonadal Steroid Hormones / blood. Premenopause
  • [MeSH-minor] Adult. Androgens / blood. Case-Control Studies. Estradiol / blood. Estradiol / metabolism. Estrogens / blood. Female. Humans. Logistic Models. Nurses / statistics & numerical data. Odds Ratio. Ovarian Follicle / metabolism. Prospective Studies. Risk Assessment. Risk Factors. Sex Hormone-Binding Globulin / metabolism. Surveys and Questionnaires. United States / epidemiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2007 Mar 7;99(5):408-9; author reply 409-10 [17341734.001]
  • (PMID = 17018787.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA50385; United States / NCI NIH HHS / CA / CA67262; United States / NCI NIH HHS / CA / R25 CA098566-02; United States / NCI NIH HHS / CA / T32 CA090001-281
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogens; 0 / Gonadal Steroid Hormones; 0 / Sex Hormone-Binding Globulin; 4TI98Z838E / Estradiol
  •  go-up   go-down


81. Smeets R, Kolk A, Gerressen M, Driemel O, Maciejewski O, Hermanns-Sachweh B, Riediger D, Stein JM: A new biphasic osteoinductive calcium composite material with a negative Zeta potential for bone augmentation. Head Face Med; 2009;5:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the present study was to analyze the osteogenic potential of a biphasic calcium composite material (BCC) with a negative surface charge for maxillary sinus floor augmentation.
  • In a 61 year old patient, the BCC material was used in a bilateral sinus floor augmentation procedure.
  • The BCC was biocompatible and replaced by new mineralized bone after being resorbed completely.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oral Maxillofac Implants. 1999 Nov-Dec;14(6):869-78 [10612926.001]
  • [Cites] Acta Biomater. 2008 Mar;4(2):397-402 [18054299.001]
  • [Cites] J Biomed Mater Res. 2001 Jun 5;55(3):387-95 [11255192.001]
  • [Cites] Clin Oral Implants Res. 2001 Aug;12(4):379-84 [11488868.001]
  • [Cites] J Periodontol. 2001 Jul;72(7):911-20 [11495140.001]
  • [Cites] J Biomed Mater Res. 2001 Dec 5;57(3):366-73 [11523031.001]
  • [Cites] Int J Oral Maxillofac Implants. 2001 Sep-Oct;16(5):681-92 [11669251.001]
  • [Cites] J Dent Res. 2001 Oct;80(10):1925-9 [11706953.001]
  • [Cites] Eur Spine J. 2001 Oct;10 Suppl 2:S96-101 [11716023.001]
  • [Cites] Int J Periodontics Restorative Dent. 2002 Oct;22(5):503-8 [12449310.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2004 Feb 15;68(2):199-208 [14737769.001]
  • [Cites] J Biomed Mater Res A. 2004 Sep 1;70(3):436-41 [15293317.001]
  • [Cites] J Oral Surg. 1980 Aug;38(8):613-6 [6993637.001]
  • [Cites] Dent Clin North Am. 1986 Apr;30(2):207-29 [3516738.001]
  • [Cites] Clin Orthop Relat Res. 1988 Jul;(232):127-38 [2838207.001]
  • [Cites] J Oral Maxillofac Surg. 1989 Mar;47(3):238-42 [2646403.001]
  • [Cites] Int J Oral Maxillofac Implants. 1988 Fall;3(3):209-14 [3074053.001]
  • [Cites] Int J Oral Maxillofac Implants. 1993;8(5):523-8 [8112791.001]
  • [Cites] Calcif Tissue Int. 1994 Aug;55(2):151-8 [7953981.001]
  • [Cites] J Biomed Mater Res. 1997 Mar 15;34(4):507-17 [9054534.001]
  • [Cites] Biochem Cell Biol. 1997;75(1):81-7 [9192077.001]
  • [Cites] Clin Oral Implants Res. 1998 Feb;9(1):59-64 [9590946.001]
  • [Cites] Clin Oral Implants Res. 1998 Apr;9(2):107-16 [9663038.001]
  • [Cites] Int J Periodontics Restorative Dent. 1998 Jun;18(3):227-39 [9728105.001]
  • [Cites] Int J Oral Maxillofac Implants. 1998 Nov-Dec;13(6):866-73 [9857600.001]
  • [Cites] Orthop Clin North Am. 1999 Oct;30(4):615-23 [10471766.001]
  • [Cites] Clin Oral Implants Res. 2004 Dec;15(6):724-32 [15533134.001]
  • [Cites] Biomaterials. 2005 Jun;26(17):3395-404 [15621228.001]
  • [Cites] Biomaterials. 2005 Dec;26(34):6818-26 [15955555.001]
  • [Cites] Int J Periodontics Restorative Dent. 2006 Feb;26(1):79-85 [16515099.001]
  • [Cites] Int J Periodontics Restorative Dent. 2006 Apr;26(2):113-25 [16642900.001]
  • [Cites] Implant Dent. 2006 Jun;15(2):197-207 [16766904.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Aug;35(8):708-13 [16690249.001]
  • [Cites] Int J Periodontics Restorative Dent. 2006 Oct;26(5):471-81 [17073357.001]
  • [Cites] J Mater Sci Mater Med. 2008 Feb;19(2):667-75 [17619955.001]
  • [Cites] Clin Oral Implants Res. 2000 Jun;11(3):217-29 [11168213.001]
  • (PMID = 19523239.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Substitutes; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2706807
  •  go-up   go-down


82. Dong X, Reddy GB: Soil bacterial communities in constructed wetlands treated with swine wastewater using PCR-DGGE technique. Bioresour Technol; 2010 Feb;101(4):1175-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that the bacterial colony forming units (CFU) and the average concentrations of total nitrogen, NH(4)(+), total phosphorous (TP) and PO(4)(3-) from the influent to the effluent decreased.
  • The NH(4)(+) and the PO(4)(3-) concentrations showed the most dramatic changes, with decreases of 39.97% and 16.92%, respectively.
  • Bacterium species distributions strongly correlated with the concentrations of TP, NH(4)(+) and the PO(4)(3-).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822421.001).
  • [ISSN] 1873-2976
  • [Journal-full-title] Bioresource technology
  • [ISO-abbreviation] Bioresour. Technol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


83. Scheithauer BK, Wos-Oxley ML, Ferslev B, Jablonowski H, Pieper DH: Characterization of the complex bacterial communities colonizing biliary stents reveals a host-dependent diversity. ISME J; 2009 Jul;3(7):797-807
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the complex bacterial communities colonizing biliary stents reveals a host-dependent diversity.
  • This study provides a comprehensive survey of the spatial and temporal bacterial composition of biliary stent biofilms.
  • The bacterial diversity, distribution and dynamics of 59 biliary and 4 pancreatic stent communities from 40 patients being treated at two different hospitals, which implant stents either simultaneously or consecutively, were characterized by single-strand conformation polymorphism (SSCP) analysis.
  • Co-colonization of Veillonella sp., Streptococcus anginosus and organisms closely related to Fusobacterium nucleatum revealed a potentially important attachment and survival strategy that has yet to be reported in biliary stents.
  • This work reveals a more complete survey of the identities of bacterial species that form biofilms in biliary stents, their co-colonization patterns and the natural variation in species composition between different patients, hospitals and locations along the stent.

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19360025.001).
  • [ISSN] 1751-7370
  • [Journal-full-title] The ISME journal
  • [ISO-abbreviation] ISME J
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU704129/ EU704130/ EU704131/ EU704132/ EU704133/ EU704134/ EU704135/ EU704136/ EU704137/ EU704138/ EU704139/ EU704140/ EU704141/ EU704142/ EU704143/ EU704144/ EU704145/ EU704146/ EU704147/ EU704148/ EU704149/ EU704150/ EU704151/ EU704152/ EU704153/ EU704154/ EU704155/ EU704156/ EU704157/ EU704158/ EU704159/ EU704160/ EU704161/ EU704162/ EU704163/ EU704164/ EU704165/ EU704166/ EU704167/ EU704168/ EU704169/ EU704170/ EU704171/ EU704172/ EU704173/ EU704174/ EU704175/ EU704176/ EU704177/ EU704178/ EU704179/ EU704180/ EU704181/ EU704182/ EU704183/ EU704184/ EU704185/ EU704186/ EU704187/ EU704188/ EU704189/ EU704190/ EU704191/ EU704192/ EU704193/ EU704194/ EU704195/ EU704196/ EU704197/ EU704198/ EU704199/ EU704200/ EU704201/ EU704202/ EU704203/ EU704204/ EU704205/ EU704206/ EU704207/ EU704208/ EU704209/ EU704210/ EU704211/ EU704212/ EU704213/ EU704214/ EU704215/ EU704216/ EU704217/ EU704218/ EU704219/ EU704220/ EU704221/ EU704222/ EU704223/ EU704224/ EU704225/ EU704226/ EU704227/ EU704228/ EU704229/ EU704230/ EU704231/ EU704232/ EU704233/ EU704234/ EU704235/ EU704236/ EU704237/ EU704238/ EU704239/ EU704240/ EU704241/ EU704242/ EU704243/ EU704244/ EU704245/ EU704246/ EU704247/ EU704248/ EU704249/ EU704250/ EU915501/ EU915502/ EU915503/ EU915504
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S
  •  go-up   go-down


84. Wang Z, Xu Y, Tang J, Ma H, Qin J, Lu C, Wang X, Hu Z, Wang X, Shen H: A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women. Breast Cancer Res Treat; 2009 Nov;118(1):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women.
  • RecQ helicases play a central role in maintaining genome stability and may interact with some important cancer-related proteins such as BRCA1.
  • Mutations of the human RecQ helicase genes WRN and BLM lead to rare autosomal recessive disorders, Werner and Bloom syndromes, which are associated with premature aging and cancer predisposition, including breast cancer.
  • In this case-control study of 1,004 breast cancer cases and 1,008 controls, we tested the hypothesis that non-conservative amino acid exchanges in WRN (leu1074Phe), BLM (Met298Thr) and BRCA1 (Pro871Leu) are independently or jointly associated with the risk of breast cancer in Chinese women.
  • We found that the variant genotype of WRN Leu1074Phe was associated with a 1.36-fold significantly increased risk of breast cancer (OR = 1.36, 95% CI = 1.06-1.74).
  • Subjects carrying Phe/Phe genotype and with earlier age at menarche had 3.58-fold increased risk of breast cancer (OR = 3.58, 95% CI = 2.54-5.05).
  • These findings indicate that WRN leu1074Phe variant may contribute to the susceptibility of breast cancer in Chinese women.
  • [MeSH-major] Breast Neoplasms / genetics. Exodeoxyribonucleases / genetics. Genes, Neoplasm. Menarche / genetics. Neoplasm Proteins / genetics. Polymorphism, Single Nucleotide. RecQ Helicases / genetics. Werner Syndrome / genetics
  • [MeSH-minor] Adult. Aged. Amino Acid Substitution. Case-Control Studies. China / epidemiology. Female. Genes, BRCA1. Genetic Predisposition to Disease. Genotype. Humans. Menopause. Middle Aged. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk

  • Genetic Alliance. consumer health - Werner's syndrome.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205873.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 3.1.- / Exodeoxyribonucleases; EC 3.6.1.- / Bloom syndrome protein; EC 3.6.1.- / WRN protein, human; EC 3.6.4.12 / RecQ Helicases
  •  go-up   go-down


85. Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS: Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br J Cancer; 2009 Feb 24;100(4):563-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women.
  • As the epidemiological pattern of breast cancer in modernising Asian countries differs greatly from that in Western countries, it is worthwhile to investigate the long-term prognoses of unilateral and bilateral breast cancer in these nations.
  • A retrospective cohort study composed of 1907 Taiwanese women was conducted to follow 1863 unilateral and 44 bilateral cases of breast cancer.
  • Time-dependent Cox regression was used to assess the risk of breast cancer death by considering the time course of unilateral and bilateral tumour development.
  • The 15-year survival rates were 68.37, 62.63, and 26.42% for unilateral, synchronous bilateral, and metachronous bilateral breast cancer, respectively.
  • After adjusting for significant prognostic factors, the risk of death for overall bilateral breast cancer was 2.50-fold greater (95% CI, 1.43-4.37) compared to unilateral breast cancer.
  • The corresponding figures were 1.12-fold (95% CI, 0.42-3.02) and 6.11-fold (95% CI, 3.14-11.89) for synchronous and metachronous bilateral breast cancer, respectively.
  • Taiwanese women, who are frequently diagnosed with breast cancer before 50 years of age, showed poorer survival for metachronous bilateral than for synchronous bilateral or unilateral breast cancer.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 May 27;355(9218):1869-74 [10866443.001]
  • [Cites] Eur J Cancer. 2008 Dec;44(18):2774-80 [19027287.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1117-24 [11571945.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):901-6 [14712495.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):27-30; discussion 31 [14718270.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3002-11 [6498774.001]
  • [Cites] Aust N Z J Surg. 1989 Jan;59(1):35-7 [2913992.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1819-27 [8230262.001]
  • [Cites] Cancer. 1993 Dec 15;72(12):3629-35 [8252478.001]
  • [Cites] Am J Epidemiol. 1995 Dec 15;142(12):1255-64 [7503045.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):143-9 [8531968.001]
  • [Cites] Int J Epidemiol. 1996 Feb;25(1):40-5 [8666502.001]
  • [Cites] Am J Clin Oncol. 1997 Dec;20(6):541-5 [9391536.001]
  • [Cites] Int J Oncol. 1999 Jun;14(6):1103-9 [10339665.001]
  • [Cites] Fam Cancer. 2004;3(3-4):249-57 [15516849.001]
  • [Cites] Int J Cancer. 2005 Jan 10;113(2):302-6 [15386413.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1986-90 [16103449.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):221-8 [16544057.001]
  • [Cites] BMC Cancer. 2006;6:261 [17078893.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2360-8 [17515570.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1017-20 [17471561.001]
  • [Cites] N Engl J Med. 2007 Jul 12;357(2):115-23 [17625123.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1437-42 [17627009.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4210-6 [17878475.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3324-30 [18612148.001]
  • [Cites] Cancer Detect Prev. 2008;32(2):156-61 [18632223.001]
  • [Cites] Cancer. 2001 May 15;91(10):1845-53 [11346865.001]
  • (PMID = 19190627.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653740
  •  go-up   go-down


86. Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, García MJ, Osorio A, Blesa D, Stratton MR, Weber BL, Cigudosa JC, Rahman N, Nathanson KL, Benítez J: Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. Clin Cancer Res; 2007 Dec 15;13(24):7305-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.
  • PURPOSE: Familial breast cancer represents 5% to 10% of all breast tumors.
  • Mutations in the two known major breast cancer susceptibility genes, BRCA1 and BRCA2, account for a minority of familial breast cancer, whereas families without mutations in these genes (BRCAX group) account for 70% of familial breast cancer cases.
  • EXPERIMENTAL DESIGN: To better characterize and define the genomic differences between the three classes of familial tumors and sporadic malignancies, we have analyzed 19 BRCA1, 24 BRCA2, and 31 BRCAX samples from familial breast cancer patients and 19 sporadic breast tumors using a 1-Mb resolution bacterial artificial chromosome array-based comparative genomic hybridization.
  • There were common genomic alterations present in all breast cancer groups, such as gains of 1q and 16p or losses of 8ptel-p12 and 16q.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Genes, BRCA1. Genes, BRCA2. Genomic Instability. Receptors, Estrogen / metabolism
  • [MeSH-minor] Chromosomes, Artificial, Bacterial. Female. Genetic Predisposition to Disease. Humans. Mutation. Nucleic Acid Hybridization


87. Homaei-Shandiz F, Ghavam-Nassiri MR, Sharifi N, Homaei-Shandiz AH, Taghizadeh-Kermani A, Torshizi SA, Ghafarzadegan K: Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer. Saudi Med J; 2006 Dec;27(12):1810-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the relationship between human epidermal growth factor receptor-2/neu (c-erbB-2) amplification and pathologic grading in patients with breast cancer.
  • OBJECTIVE: The human epidermal growth factor receptor-2 (HER-2)/neu is a proto-oncogene that is amplified in 10-30% of breast cancers.
  • We studied the relationship between its amplification and different histological gradings of breast cancer.
  • METHODS: We studied 196 patients diagnosed with breast cancer in 2005 at the Omid and Ghaem Training Hospital, Mashhad Medical University, Iran.
  • RESULTS: Sixty-seven (34.2%) cases were HER-2/neu positive and 129 (65.8%) cases were HER-2/neu negative.
  • Overexpression of HER-2/neu was significantly higher in breast cancer patients <30 years (50% versus 33.3%, p=0.034).
  • Twelve (17.5%) of HER-2/neu positive cases were metastatic and only 4 (3.1%) of HER-2/neu negative cases had metastasis (p=0.051).
  • CONCLUSION: HER-2/neu gene amplification or its overexpression is detected in approximately 34.2% of breast cancer cases.
  • Patients with HER-2/neu positive breast cancer have higher stage and grade diseases.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Gene Amplification. Gene Expression Regulation, Neoplastic / genetics. Receptor, ErbB-2 / genetics


88. Kleinerman RA: Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatr Radiol; 2009 Feb;39 Suppl 1:S27-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Major advances in pediatric cancer treatment have resulted in substantial improvements in survival.
  • However, concern has emerged about the late effects of cancer therapy, especially radiation-related second cancers.
  • Studies of childhood cancer patients with inherited cancer syndromes can provide insights into the interaction between radiation and genetic susceptibility to multiple cancers.
  • Children with retinoblastoma (Rb), neurofibromatosis type 1 (NF1), Li-Fraumeni syndrome (LFS), and nevoid basal cell carcinoma syndrome (NBCCS) are at substantial risk of developing radiation-related second and third cancers.
  • Studies of NF1 patients irradiated for optic pathway gliomas have reported increased risks of developing another cancer associated with radiotherapy.
  • Children with NBCCS are very sensitive to radiation and develop multiple basal cell cancers in irradiated areas.
  • [MeSH-major] Genetic Predisposition to Disease. Neoplasms, Radiation-Induced / genetics. Neoplasms, Second Primary / genetics. Neoplastic Syndromes, Hereditary / radiotherapy
  • [MeSH-minor] Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / radiotherapy. Child. Humans. Li-Fraumeni Syndrome. Neurofibromatosis 1 / genetics. Neurofibromatosis 1 / radiotherapy. Radiation Dosage. Retinal Neoplasms / genetics. Retinal Neoplasms / radiotherapy. Retinoblastoma / genetics. Retinoblastoma / radiotherapy

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] Health Phys. 2003 Jul;85(1):47-59 [12852471.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Br J Cancer. 1986 May;53(5):661-71 [3718823.001]
  • [Cites] Medicine (Baltimore). 1987 Mar;66(2):98-113 [3547011.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5358-62 [3409256.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] N Engl J Med. 1992 May 14;326(20):1309-15 [1565144.001]
  • [Cites] Radiat Res. 1995 Mar;141(3):259-77 [7871153.001]
  • [Cites] Radiat Res. 1996 May;145(5):595-601 [8619025.001]
  • [Cites] Int J Cancer. 1996 Aug 7;67(4):515-9 [8759610.001]
  • [Cites] JAMA. 1997 Oct 15;278(15):1262-7 [9333268.001]
  • [Cites] Cancer Causes Control. 1997 Nov;8(6):865-71 [9427429.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):583-93 [15667981.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2272-9 [15800318.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):271-3 [16226702.001]
  • [Cites] J Med Genet. 2006 Apr;43(4):289-94 [16155191.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] Pediatr Radiol. 2006 Sep;36 Suppl 2:121-5 [16862418.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2001-6 [16642469.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):24-31 [17202110.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2233-40 [17557301.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Natl Cancer Inst. 2008 Mar 19;100(6):428-36 [18334707.001]
  • [Cites] JAMA. 2008 Mar 19;299(11):1315-9 [18349092.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):228-35 [18571337.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):667-72 [10793343.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):431-6 [11878577.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Nat Rev Cancer. 2002 Feb;2(2):124-32 [12635175.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • (PMID = 19083227.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010131-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  • [Other-IDs] NLM/ NIHMS75740; NLM/ PMC2656401
  •  go-up   go-down


89. Gurgel CA, Ramos EA, Azevedo RA, Sarmento VA, da Silva Carvalho AM, dos Santos JN: Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study. J Mol Histol; 2008 Jun;39(3):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Immunohistochemical technique was performed using the EnVision System in 37 cases of KOTs.
  • No difference in the immunostaining for these proteins was observed between primary and recurrent KOTs (Ki-67: P = 0.5591; p53: P = 0.9847; p63: P = 0.9127), or between KOTs associated with Nevoid Basal Cell Carcinoma Syndrome (NBCCS) and sporadic KOTs (Ki-67: P = 0.7013; p53: P = 0.3197; p63: P = 0.2427).
  • In addition, p63 immunostaining may represent immaturity of keratinocytes in KOTs, and suggests that this protein may participate in the regulation of epithelial cell differentiation.
  • [MeSH-minor] Antibodies. Cell Count. Humans. Immunohistochemistry. Transcription Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 1989 Jan;92 ( Pt 1):123-30 [2674163.001]
  • [Cites] Histopathology. 2005 Dec;47(6):582-6 [16324195.001]
  • [Cites] J Clin Pathol. 1992 Nov;45(11):1007-10 [1452774.001]
  • [Cites] J Oral Pathol Med. 1995 Oct;24(9):393-7 [8537911.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] J Pathol. 1998 Apr;184(4):348-50 [9664899.001]
  • [Cites] J Endod. 2001 Jul;27(7):459-61 [11503996.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Oral Oncol. 2004 Nov;40(10):985-91 [15509489.001]
  • [Cites] Exp Cell Res. 2006 Apr 1;312(6):695-706 [16406339.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):841-6 [14584101.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jan;34(1):6-9 [11733180.001]
  • [Cites] J Oral Pathol Med. 1995 May;24(5):221-6 [7542341.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Feb;64(2):308-16 [16413905.001]
  • [Cites] J Pathol. 2002 Dec;198(4):417-27 [12434410.001]
  • [Cites] Cell. 2007 May 4;129(3):523-36 [17482546.001]
  • [Cites] Arch Oral Biol. 1995 Dec;40(12):1081-4 [8850645.001]
  • [Cites] Int J Oral Maxillofac Surg. 2005 Sep;34(6):668-73 [16053892.001]
  • [Cites] Am J Pathol. 1991 Apr;138(4):867-73 [2012175.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Oral Oncol. 2002 Jul;38(5):407-15 [12110333.001]
  • [Cites] Histopathology. 1993 Apr;22(4):355-60 [8514278.001]
  • [Cites] J Contemp Dent Pract. 2000 Feb 15;1(2):60-74 [12167890.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] J Dent Res. 1999 Jul;78(7):1345-53 [10403462.001]
  • [Cites] Biochemistry (Mosc). 2005 Sep;70(9):955-71 [16266265.001]
  • [Cites] Regen Med. 2006 Jan;1(1):45-57 [17465819.001]
  • [Cites] J Oral Pathol Med. 2001 Aug;30(7):434-42 [11488422.001]
  • [Cites] Oral Dis. 2004 Jan;10(1):22-6 [14996290.001]
  • [Cites] J Oral Pathol Med. 2005 May;34(5):280-6 [15817071.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jun 24;273(1):342-6 [10873608.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):38-44 [16359856.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] J Oral Pathol Med. 1996 May;25(5):249-55 [8835823.001]
  • [Cites] Curr Biol. 1992 Nov;2(11):581-3 [15336029.001]
  • [Cites] J Oral Pathol Med. 2006 Feb;35(2):75-80 [16430736.001]
  • [Cites] Oral Oncol. 2002 Apr;38(3):219-26 [11978543.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10 ):759-68 [17050669.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1A):175-81 [16475695.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Jul;35(7):673-5 [16687239.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] J Oral Pathol Med. 2000 Nov;29(10):477-82 [11048963.001]
  • (PMID = 18256893.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Ki-67 Antigen; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


90. Newman MD, Weinberg JM: Topical therapy in the treatment of actinic keratosis and basal cell carcinoma. Cutis; 2007 Apr;79(4 Suppl):18-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical therapy in the treatment of actinic keratosis and basal cell carcinoma.
  • Actinic keratosis (AK) is an evolving malignant cutaneous neoplasm.
  • AK also is known as solar keratosis and squamous cell carcinoma (SCC) in situ, either solar keratotic type or keratinocytic intraepidermal neoplasia.
  • Topical treatment of basal cell carcinoma (BCC) with imiquimod also will be discussed.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Keratosis / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17508492.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase Inhibitors; 0 / Retinoids; 0 / Tubulin Modulators
  • [Number-of-references] 44
  •  go-up   go-down


91. Ahlgrimm-Siess V, Horn M, Koller S, Ludwig R, Gerger A, Hofmann-Wellenhof R: Monitoring efficacy of cryotherapy for superficial basal cell carcinomas with in vivo reflectance confocal microscopy: a preliminary study. J Dermatol Sci; 2009 Jan;53(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring efficacy of cryotherapy for superficial basal cell carcinomas with in vivo reflectance confocal microscopy: a preliminary study.
  • BACKGROUND: Superficial BCCs (sBCCs) usually appear as multiple lesions in chronic sun-damaged skin of elderly people and may show a destructive growth if left untreated.
  • Non-invasive treatment modalities, such as cryotherapy have been employed for sBCCs, all failing to provide tissue for confirming diagnosis and assessing adequacy of tumour removal.
  • Reflectance confocal microscopy (RCM), a new non-invasive imaging technique has proven to be a useful tool for detection of basal cell carcinoma in vivo.
  • RESULTS: Characteristic RCM-features of BCC were present in all lesions before cryotherapy.
  • Five hours after cryotherapy, all 10 sBCCs showed small bright round to polygonal structures at basal layer and black round to oval areas of varying size with such bright structures floating therein, correlating to cell necrosis and incipient blistering.
  • Eight sBCCs showed also cell necrosis in upper dermis.
  • CONCLUSION: Early cell necrosis within upper dermal structures seems to correlate with ablation of overlying tumour tissue.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Cryotherapy / methods. Microscopy, Confocal. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Aged, 80 and over. Biopsy. Female. Humans. Male. Necrosis. Skin / pathology. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829267.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


92. Zhang G, Luo X, Sumithran E, Pua VS, Barnetson RS, Halliday GM, Khachigian LM: Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. Oncogene; 2006 Nov 23;25(55):7260-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression.
  • Squamous cell carcinoma (SCC) is an invasive malignancy of epidermal keratinocytes.
  • The transcription factor c-Jun is expressed in human SCC and another common form of invasive skin cancer, basal cell carcinoma together with the mitogenic marker-proliferating cell nuclear antigen.
  • These findings demonstrate that c-Jun regulates SCC growth and suggest that DNAzymes targeting this transcription factor may potentially be useful as inhibitors of cutaneous carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Division / physiology. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Proto-Oncogene Proteins c-jun / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785994.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Catalytic; 0 / Matrix Metalloproteinase Inhibitors; 0 / Proto-Oncogene Proteins c-jun; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


93. Reszec J, Sulkowski S: The expression of P53 protein and infection of human papilloma virus in conjunctival and eyelid neoplasms. Int J Mol Med; 2005 Oct;16(4):559-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate P53 protein expression and to detect HPV in the tissue samples of 45 benign (papillomas) and 38 malignant conjunctival and eyelid lesions (27 basal cell carcinomas and 11 squamous cell carcinomas).
  • We revealed P53 protein expression in 30 out of 45 (66.6%) squamous cell papillomas.
  • In the SCC and BCC groups, P53 was present in 31 out of 38 carcinomas and there was a statistically significant correlation between histological type of tumor and P53 protein expression.
  • Malignant type HPV 16 and 18 were detected in three squamous cell papillomas, two BCCs and one SCC.
  • However, we observed P53 protein expression in only two HPV-positive papillomas and one infiltrative type of BCC.
  • P53 is probably involved in the development of conjunctival and eyelid tumors due to its high rate of presence in both benign and malignant neoplasms of these organs.
  • In some cases its role in the pathogenesis of conjunctival and eyelid tumorigenesis should be considered as auxiliary.
  • [MeSH-minor] Adult. Carcinoma, Basal Cell / metabolism. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / virology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. Humans. Middle Aged. Papilloma / metabolism. Papilloma / pathology. Papilloma / virology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142387.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


94. Riemann L, Leitet C, Pommier T, Simu K, Holmfeldt K, Larsson U, Hagström A: The native bacterioplankton community in the central baltic sea is influenced by freshwater bacterial species. Appl Environ Microbiol; 2008 Jan;74(2):503-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The native bacterioplankton community in the central baltic sea is influenced by freshwater bacterial species.
  • The Baltic Sea is one of the largest brackish environments on Earth.
  • Despite extensive knowledge about food web interactions and pelagic ecosystem functioning, information about the bacterial community composition in the Baltic Sea is scarce.
  • We hypothesized that due to the eutrophic low-salinity environment and the long water residence time (>5 years), the bacterioplankton community from the Baltic proper shows a native "brackish" composition influenced by both freshwater and marine phylotypes.
  • The bacterial community composition in surface water (3-m depth) was examined at a single station throughout a full year.
  • Denaturing gradient gel electrophoresis (DGGE) showed that the community composition changed over the year.
  • Further, it indicated that at the four extensive samplings (16S rRNA gene clone libraries and bacterial isolates from low- and high-nutrient agar plates and seawater cultures), different bacterial assemblages associated with different environmental conditions were present.
  • Overall, the sequencing of 26 DGGE bands, 160 clones, 209 plate isolates, and 9 dilution culture isolates showed that the bacterial assemblage in surface waters of the central Baltic Sea was dominated by Bacteroidetes but exhibited a pronounced influence of typical freshwater phylogenetic groups within Actinobacteria, Verrucomicrobia, and Betaproteobacteria and a lack of typical marine taxa.
  • This first comprehensive analysis of bacterial community composition in the central Baltic Sea points to the existence of an autochthonous estuarine community uniquely adapted to the environmental conditions prevailing in this brackish environment.
  • [MeSH-major] Bacteria / growth & development. Fresh Water / microbiology. Plankton / growth & development. Seawater / microbiology
  • [MeSH-minor] Actinobacteria / classification. Actinobacteria / genetics. Actinobacteria / growth & development. Animals. Bacteroidetes / classification. Bacteroidetes / genetics. Bacteroidetes / growth & development. Betaproteobacteria / classification. Betaproteobacteria / genetics. Betaproteobacteria / growth & development. Ecosystem. Molecular Sequence Data. Phylogeny. Polymerase Chain Reaction. RNA, Ribosomal, 16S / genetics. Sequence Analysis, DNA

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Environ Microbiol. 2003 Oct;69(10):5875-83 [14532039.001]
  • [Cites] Appl Environ Microbiol. 2003 Sep;69(9):5248-54 [12957910.001]
  • [Cites] Appl Environ Microbiol. 2003 Nov;69(11):6610-9 [14602620.001]
  • [Cites] Environ Microbiol. 2004 Mar;6(3):242-53 [14871208.001]
  • [Cites] Appl Environ Microbiol. 2004 Mar;70(3):1494-505 [15006771.001]
  • [Cites] Appl Environ Microbiol. 2004 Apr;70(4):2445-51 [15066843.001]
  • [Cites] Nature. 2004 Jul 29;430(6999):551-4 [15282603.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):6955-9 [2413450.001]
  • [Cites] J Bacteriol. 1991 Jul;173(14):4371-8 [2066334.001]
  • [Cites] Appl Environ Microbiol. 1997 Mar;63(3):983-9 [9055415.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3389-402 [9254694.001]
  • [Cites] Appl Environ Microbiol. 2000 Feb;66(2):578-87 [10653721.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1902-6 [10988064.001]
  • [Cites] Appl Environ Microbiol. 2000 Nov;66(11):4634-40 [11055904.001]
  • [Cites] Appl Environ Microbiol. 2000 Nov;66(11):5053-65 [11055963.001]
  • [Cites] Nucleic Acids Res. 2001 Jan 1;29(1):173-4 [11125082.001]
  • [Cites] Appl Environ Microbiol. 2002 Jan;68(1):379-88 [11772648.001]
  • [Cites] Appl Environ Microbiol. 2002 Feb;68(2):505-18 [11823184.001]
  • [Cites] Appl Environ Microbiol. 2002 Aug;68(8):3878-85 [12147485.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1442-51 [12620827.001]
  • [Cites] Appl Environ Microbiol. 2003 Jun;69(6):3607-16 [12788769.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3497-500 [12824352.001]
  • [Cites] Appl Environ Microbiol. 1997 Sep;63(9):3359-66 [9292985.001]
  • [Cites] Appl Environ Microbiol. 1997 Nov;63(11):4237-42 [9361410.001]
  • [Cites] Genome Res. 1998 Mar;8(3):186-94 [9521922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3807-12 [10097119.001]
  • [Cites] Appl Environ Microbiol. 1999 Jul;65(7):3192-204 [10388721.001]
  • [Cites] Appl Environ Microbiol. 1999 Aug;65(8):3721-6 [10427073.001]
  • [Cites] Appl Environ Microbiol. 2004 Nov;70(11):6753-66 [15528542.001]
  • [Cites] Appl Environ Microbiol. 2005 Aug;71(8):4793-800 [16085877.001]
  • [Cites] Appl Environ Microbiol. 2005 Dec;71(12):8201-6 [16332803.001]
  • [Cites] Appl Environ Microbiol. 2005 Dec;71(12):8402-10 [16332828.001]
  • [Cites] Appl Environ Microbiol. 2006 May;72(5):3489-97 [16672495.001]
  • [Cites] Trends Microbiol. 2006 Jun;14(6):257-63 [16679014.001]
  • [Cites] Ecology. 2006 Aug;87(8):2068-79 [16937646.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13104-9 [16938845.001]
  • [Cites] Appl Environ Microbiol. 2006 Sep;72(9):5734-41 [16957188.001]
  • [Cites] Appl Environ Microbiol. 2006 Sep;72(9):6004-11 [16957222.001]
  • [Cites] Mol Ecol. 2007 Feb;16(4):867-80 [17284217.001]
  • [Cites] Environ Microbiol. 2007 May;9(5):1253-66 [17472638.001]
  • [Cites] Appl Environ Microbiol. 2003 Nov;69(11):6481-8 [14602603.001]
  • (PMID = 18039821.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AY962019/ AY962020/ AY962021/ DQ063002/ DQ063003/ DQ063004/ DQ063005/ DQ063006/ DQ063007/ DQ063008/ DQ063009/ DQ063010/ DQ063011/ DQ063012/ DQ063013/ DQ063014/ DQ063015/ DQ063016/ DQ063017/ DQ063018/ DQ063019/ DQ063020/ DQ063021/ DQ063022/ DQ063023/ DQ063024/ DQ063025/ DQ063026/ DQ063027/ DQ063028/ DQ063029/ DQ063030/ DQ063031/ DQ063032/ DQ063033/ DQ063034/ DQ063035/ DQ063036/ DQ063037/ DQ063038/ DQ063039/ DQ063040/ DQ063041/ DQ063042/ DQ063043/ DQ063044/ DQ063045/ DQ063046/ DQ063047/ DQ063048/ DQ063049/ DQ063050/ DQ063051/ DQ063052/ DQ063053/ DQ063054/ DQ063055/ DQ063056/ DQ063057/ DQ063058/ DQ063059/ DQ063060/ DQ063061/ DQ063062/ DQ063063/ DQ063064/ DQ063065/ DQ063066/ DQ063067/ DQ063068/ DQ063069/ DQ063070/ DQ063071/ DQ063072/ DQ063073/ DQ063101/ DQ063102/ DQ063103/ DQ063104/ DQ063105/ DQ063106/ DQ063107/ DQ063108/ DQ063109/ DQ063110/ DQ063111/ DQ063112/ DQ063113/ DQ063114/ DQ063115/ DQ063116/ DQ063117/ DQ063118/ DQ063119/ DQ063120/ DQ063121/ DQ063122/ DQ063123/ DQ063124/ DQ063125/ DQ063126/ DQ063127/ DQ063128/ DQ063129/ DQ063130/ DQ063131/ DQ063132/ DQ063133/ DQ063134/ DQ063135/ DQ063136/ DQ063137/ DQ063138/ DQ063139/ DQ063140/ DQ063141/ DQ063142/ DQ063143/ DQ063144/ DQ063145/ DQ063146/ DQ063147/ DQ063148/ DQ063149/ DQ063150/ DQ063151/ DQ063152/ DQ063153/ DQ063154/ DQ063155/ DQ063156/ DQ063157/ DQ063158/ DQ063159/ DQ063160/ DQ063161/ DQ063162/ DQ063163/ DQ063164/ DQ063165/ DQ063166/ DQ063167/ DQ063168/ DQ063169/ DQ063170/ DQ063171/ DQ063172/ DQ063173/ DQ063174/ DQ063175/ DQ063176/ DQ063177/ DQ063178/ DQ063179/ DQ063180/ DQ063181/ DQ063182/ DQ063183/ DQ063184/ DQ063185/ DQ063186/ DQ063187/ DQ063188/ DQ063189/ DQ063190/ DQ063191/ DQ063192/ DQ063193/ DQ063194/ DQ063195/ DQ063196/ DQ063197/ DQ063198/ DQ063199/ DQ063200/ DQ063201/ DQ063202/ DQ063203/ DQ063204/ DQ063205/ DQ063206/ DQ063207/ DQ063208/ DQ063209/ DQ063210/ DQ063211/ DQ063212/ DQ063213/ DQ063214/ DQ063215/ DQ063216/ DQ270271/ DQ270272/ DQ270273/ DQ270274/ DQ270275/ DQ270276/ DQ270277/ DQ270278/ DQ270279/ DQ270280/ DQ270281/ DQ270282/ DQ270283/ DQ270284/ DQ270285/ DQ270286/ DQ270287/ DQ270288/ DQ270289/ DQ270290/ DQ270291/ DQ270292/ DQ270293/ DQ270294/ DQ270295/ DQ270296/ EF627821/ EF627822/ EF627823/ EF627824/ EF627825/ EF627826/ EF627827/ EF627828/ EF627829/ EF627830/ EF627831/ EF627832/ EF627833/ EF627834/ EF627835/ EF627836/ EF627837/ EF627838/ EF627839/ EF627840/ EF627841/ EF627842/ EF627843/ EF627844/ EF627845/ EF627846/ EF627847/ EF627848/ EF627849/ EF627850/ EF627851/ EF627852/ EF627853/ EF627854/ EF627855/ EF627856/ EF627857/ EF627858/ EF627859/ EF627860/ EF627861/ EF627862/ EF627863/ EF627864/ EF627865/ EF627866/ EF627867/ EF627868/ EF627869/ EF627870/ EF627871/ EF627872/ EF627873/ EF627874/ EF627875/ EF627876/ EF627877/ EF627878/ EF627879/ EF627880/ EF627881/ EF627882/ EF627883/ EF627884/ EF627885/ EF627886/ EF627887/ EF627888/ EF627889/ EF627890/ EF627891/ EF627892/ EF627893/ EF627894/ EF627895/ EF627896/ EF627897/ EF627898/ EF627899/ EF627900/ EF627901/ EF627902/ EF627903/ EF627904/ EF627905/ EF627906/ EF627907/ EF627908/ EF627909/ EF627910/ EF627911/ EF627912/ EF627913/ EF627914/ EF627915/ EF627916/ EF627917/ EF627918/ EF627919/ EF627920/ EF627921/ EF627922/ EF627923/ EF627924/ EF627925/ EF627926/ EF627927/ EF627928/ EF627929/ EF627930/ EF627931/ EF627932/ EF627933/ EF627934/ EF627935/ EF627936/ EF627937/ EF627938/ EF627939/ EF627940/ EF627941/ EF627942/ EF627943/ EF627944/ EF627945/ EF627946/ EF627947/ EF627948/ EF627949/ EF627950/ EF627951/ EF627952/ EF627953/ EF627954/ EF627955/ EF627956/ EF627957/ EF627958/ EF627959/ EF627960/ EF627961/ EF627962/ EF627963/ EF627964/ EF627965/ EF627966/ EF627967/ EF627968/ EF627969/ EF627970/ EF627971
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Ribosomal, 16S
  • [Other-IDs] NLM/ PMC2223248
  •  go-up   go-down


95. Moskalik K, Kozlov A, Demin E, Boiko E: The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers. Photomed Laser Surg; 2009 Apr;27(2):345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of facial skin cancer treatment with high-energy pulsed neodymium and Nd:YAG lasers.
  • OBJECTIVE: The aim of this study was to assess the curative and cosmetic efficacy of treatment for facial skin cancer using neodymium laser irradiation.
  • BACKGROUND DATA: Due to the complex anatomy of the area, therapy for facial skin cancer is difficult.
  • MATERIALS AND METHODS: Laser irradiation was used for the treatment of 3461 patients with 3624 facial skin cancer lesions of stages T(1-2)N(0)M(0:) 3346 basal cell skin cancers, 188 limited basal cell skin cancer recurrences, and 90 squamous cell skin cancers.
  • RESULTS: Patients with basal cell skin cancer treated by irradiation with the Nd laser developed recurrences in 1.8% of cases, and patients treated with the Nd:YAG laser had a recurrence rate of 2.5%.
  • Recurrences following treatment for basal cell skin cancer, and those of squamous cell skin cancer, after irradiation with the Nd laser appeared in 3.7% and 4.4% of patients, respectively.
  • Overall, the frequency of facial skin cancer recurrences after treatment with laser irradiation was 2.1% of all the irradiated tumors.
  • CONCLUSION: Neodymium laser irradiation is an effective method to treat facial skin cancer of stages T(1-2)N(0)M(0), and results in acceptable cosmetic results.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Facial Neoplasms / radiotherapy. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Facial Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382838.001).
  • [ISSN] 1557-8550
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Soysal HG, Soysal E, Markoç F, Ardiç F: Basal cell carcinoma of the eyelids and periorbital region in a Turkish population. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):201-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the eyelids and periorbital region in a Turkish population.
  • PURPOSE: To review the clinical and histopathologic features, treatment, and outcomes of eyelid basal cell carcinomas.
  • METHODS: The clinical records and histopathologic specimens of 311 patients with eyelid basal cell carcinomas were reviewed and analyzed retrospectively.
  • The most common histologic subtypes were infiltrative, nodular, and basosquamous basal cell carcinomas.
  • Recurrent basal cell carcinomas were larger, with longer duration of lesion and a higher rate of orbital and perineural invasion.
  • Basosquamous basal cell carcinomas were more likely to have prior recurrences, larger lesion size, and the highest rate of orbital invasion.
  • CONCLUSIONS: In this large case series from a single center, the outcomes were worse than previously reported due to delay in treatment and previous inadequate treatments.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasm Recurrence, Local. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520835.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Oven Ustaalioglu BB, Bilici A, Kefeli U, Seker M, Yildirim E, Salepci T, Oncel M, Kement M, Gumus M: Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences. Oncology; 2010;79(1-2):105-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the metastatic lymph node ratio influence the disease-free survival of patients with breast cancer: single-center experiences.
  • BACKGROUND: Axillary lymph nodes (ALNs) are the most important prognostic factor for survival in breast cancer.
  • In the current study, we evaluated whether the metastatic lymph node ratio (n ratio) is important in predicting disease-free survival (DFS) for breast cancer patients.
  • MATERIAL AND METHODS: From 802 breast cancer cases, 427 patients with ALN metastasis were analyzed retrospectively.
  • RESULTS: The n ratio was significantly higher in breast cancer patients with advanced pathologic pT, pN and clinical stage, undifferentiated histology, lymphovascular and extracapsular invasion, more resected ALNs and positive progesterone receptor.
  • In the univariate analysis, multicentricity, necrosis, grade, pN stage, estrogen receptor and progesterone receptor positivity, trastuzumab and neoadjuvant chemotherapy usage, the presence of inflammatory breast cancer and n ratio were found to be important factors in predicting DFS.
  • CONCLUSIONS: The n ratio is inexpensive, easily available and a simple prognostic factor for breast cancer patients with positive ALNs.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Inflammatory Breast Neoplasms / mortality. Inflammatory Breast Neoplasms / pathology. Kaplan-Meier Estimate. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Necrosis. Neoadjuvant Therapy / methods. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21088436.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Lee B, Lim A, Lalvani A, Descamps MJ, Leonard R, Nallamala S, Lewis JS, Coombes RC, Stebbing J: The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann Oncol; 2008 Dec;19(12):2001-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer.
  • BACKGROUND: Increasing numbers of patients with early cancer undergo routine staging using computerized tomography (CT).
  • Those in whom indeterminate pulmonary nodules are visualized without the presence of other metastatic lesions represent a clinical dilemma regarding their management as early breast cancer or metastatic disease.
  • PATIENTS AND METHODS: Medical records of breast cancer patients who underwent thoracic CT scans between the years 2002 and 2008 were analyzed.
  • Those with obvious metastatic disease were excluded.
  • Thirty-four cases (4.2%) with indeterminate pulmonary nodules were identified.
  • We categorized cases by size and number of nodules.
  • In contrast, in 100% of cases with pulmonary nodules >1 cm, the nodules had progressed at follow-up (chi(2), P = 0.004).
  • CONCLUSIONS: Breast cancer cases with subcentimeter indeterminate pulmonary lesions and no evidence of metastases elsewhere are unlikely to represent metastatic disease.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1992 Nov;10(11):1810-6 [1403062.001]
  • [Cites] Surgery. 1984 Oct;96(4):801-5 [6484816.001]
  • [Cites] Radiology. 2005 Nov;237(2):395-400 [16244247.001]
  • [Cites] Thorax. 2006 Apr;61(4):331-6 [16467070.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2694-6 [16702578.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2743-9 [16702580.001]
  • [Cites] Clin Evid. 2006 Jun;(15):2331-59 [16973089.001]
  • [Cites] Clin Evid. 2006 Jun;(15):2360-92 [16973090.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4793-5 [17050863.001]
  • [Cites] J Clin Oncol. 2006 Oct 20;24(30):4801-7 [17050865.001]
  • [Cites] Lancet. 2007 Feb 17;369(9561):559-70 [17307102.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1454-5 [17416872.001]
  • [Cites] Thorac Surg Clin. 2007 May;17(2):143-58 [17626393.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):108S-130S [17873164.001]
  • [Cites] Chest. 2007 Dec;132(6):1939-48 [18079227.001]
  • [Cites] Radiol Clin North Am. 2000 May;38(3):511-24 [10855258.001]
  • [Cites] Lancet. 2000 Aug 12;356(9229):590-1; author reply 593 [10950250.001]
  • [Cites] J Thorac Imaging. 2001 Jan;16(1):65-8 [11149694.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Radiol Clin North Am. 2001 Nov;39(6):1115-35 [11699664.001]
  • [Cites] Lung Cancer. 2002 Feb;35(2):143-8 [11804686.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] Radiology. 2004 Apr;231(1):164-8 [14990809.001]
  • [Cites] Chest. 2004 Apr;125(4):1522-9 [15078769.001]
  • [Cites] J Thorac Imaging. 1994 Spring;9(2):129-34 [8207780.001]
  • (PMID = 18641008.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2733112
  •  go-up   go-down


99. Sanguinetti A, Ragusa M, De Falco M, Sperlongano P, Calzolari F, Parmeggiani D, Misso C, Piatto A, Parmeggiani U, Avenia N: [Locally advanced breast cancer in elderly patients: treatment standardised or tailored to individual needs?]. Chir Ital; 2007 Nov-Dec;59(6):829-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced breast cancer in elderly patients: treatment standardised or tailored to individual needs?].
  • Breast cancer in elderly patients occurs frequently and is often inadequately managed.
  • From 2001 to 2005 116 cases of breast cancer in elderly women (70-95 years old) were observed by our surgical units.
  • A Madden modified radical mastectomy was carried out in all cases.
  • Resection was extended to the chest-wall tissues in cases of local infiltration.
  • Surgical mortality was 10% (4 cases).
  • Eight of the 34 patients discharged died within 24 months (2 of disease progression).
  • 10 of the 26 patients (38.4%) surviving over 2 years underwent redo surgery for local relapse of disease.
  • 1) breast cancer in elderly patients is often underestimated and undertreated;.
  • 2) disease management cannot be standardized, but must be tailored to the single patient;.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Modified Radical
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Antineoplastic Agents, Hormonal / therapeutic use. Breast / pathology. Female. Follow-Up Studies. Humans. Infant, Newborn. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Reoperation. Tamoxifen / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360988.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


100. Palmero EI, Ashton-Prolla P, da Rocha JC, Vargas FR, Kalakun L, Blom MB, Azevedo SJ, Caleffi M, Giugliani R, Schüler-Faccini L: Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil. J Genet Couns; 2007 Jun;16(3):363-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characterization and risk profile of individuals seeking genetic counseling for hereditary breast cancer in Brazil.
  • Hereditary breast cancer (HBC) accounts for 5-10% of breast cancer cases and it significantly increases the lifetime risk of cancer.
  • Our objective was to evaluate the sociodemographic variables, family history of cancer, breast cancer (BC) screening practices and the risk profile of cancer affected or asymptomatic at-risk women that undergo genetic counseling for hereditary breast cancer in public Brazilian cancer genetics services.
  • The average prior probability of carrying a BRCA1/2 gene mutation was 16.7% and overall only 32% fulfilled criteria for a hereditary breast cancer syndrome as assessed by family history.
  • We conclude that a significant number of individuals at high-risk for HBC syndromes may not have access to the benefits of cancer genetic counseling in these centers.
  • Contributing factors may include insufficient training of healthcare professionals, disinformation of cancer patients; difficult access to genetic testing and/or resistance in seeking such services.
  • The identification and understanding of these barriers is essential to develop specific strategies to effectively achieve cancer risk reduction in this and other countries were clinical cancer genetics is not yet fully established.
  • [MeSH-major] BRCA2 Protein / genetics. Breast Neoplasms / genetics. Genetic Counseling / statistics & numerical data. Genetic Testing / statistics & numerical data. Neoplastic Syndromes, Hereditary / genetics. Ubiquitin-Protein Ligases / genetics






Advertisement